

CURRICULUM VITAE



CAROLINA L. HAASS-KOFFLER, PHARM.D, PH.D

TABLE OF CONTENT

CONTACT.....	2
EDUCATION	2
POSTGRADUATE TRAINING.....	2
HONORS AND AWARDS	3
MILITARY SERVICE	3
ACADEMIC APPOINTMENTS	4
HOSPITAL APPOINTMENTS AND CERTIFICATION.....	4
SERVICE TO DEPARTMENT, CENTER, UNIVERSITY, HOSPITAL	4
UNIVERSITY COMMITTEES	5
REVIEWER FOR GRANT PROPOSAL.....	5
SOCIETY AND CONFERENCE RESPONSABILITIES	6
EDITORIAL RESPONSABILITIES	6
REVIEWER RESPONSABILITIES	6
MEMBERSHIP IN SOCIETIES.....	7
FDA INVESTIGATIONAL NEW DRUGS (IND) APPLICATIONS	7
PUBLICATION LIST.....	7
ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS	7
OTHER PEER-REVIEWED PUBLICATIONS	10
BOOKS AND BOOK CHAPTERS.....	11
NON-PEER REVIEWED PUBLICATIONS.....	11
PATENTS AND PATENT APPLICATIONS	12
INTERVIEWS FOR MASS-MEDIA	12
NATIONAL ABSTRACTS PEER-REVIEWED	12
INTERNATIONAL ABSTRACTS PEER-REVIEWED	18
INVITED NATIONAL PRESENTATIONS AND SYMPOSIA.....	20
INVITED INTERNATIONAL PRESENTATIONS AND SYMPOSIA	22
GRANTS.....	22
CURRENT GRANT SUPPORT	22
PENDING GRANT SUPPORT	24
COMPLETED GRANT SUPPORT	25
UNIVERSITY TEACHING ROLES.....	26
MENTORING AND SUPERVISING ROLES	28
MENTOR TRAINING PROGRAM.....	29
HOSPITAL TEACHING ROLES	29
INDUSTRY APPOINTMENTS AND PARTNERSHIPS.....	29
<i>ADDENDUM: MENTORING AND SUPERVISING ROLES.....</i>	<i>30</i>

CAROLINA L. HAASS-KOFFLER, PHARMD, PHD

CONTACT

121 South Main Street, Providence, RI 02912
Cell: 415-519-1385 | Tel: 401-863-6624 | Fax: 401-863-6697
Email: carolina_haass-koffler@brown.edu
Website: [Clinical Neuroscience Lab](#)
Brown profile: [Carolina L Haass-Koffler](#)
COBRE: [CADRE PROJECT](#)
Twitter  : [@Carolinja2](#)
ORCID  : 0000-0002-5634-5679

EDUCATION

Undergraduate	University of California, Berkeley, CA, US Bachelor of Science (BS), Chemistry, 05/2002 Mentor: Evan Williams, PHD
Advanced Degree	University of California, San Francisco (UCSF), CA, US Doctor of Pharmacy (PHARMD) Pharmaceutical Sciences Pathway, 03/2009 Mentor: Antonello Bonci, MD
	University of Camerino (UNICAM), ITALY Doctor of Philosophy (PHD) Chemical and Pharmaceutical Sciences and Biotechnology, 5/2022 Mentor: Roberto Ciccocioppo, PHD

POSTGRADUATE TRAINING

Postdoctoral Fellowship	Ernest Gallo Clinic and Research Center Neuroscience Department University of California, San Francisco (UCSF) Specialization: Neuroscience, 05/2009-08/2012 Mentor: Selena Bartlett, PHD
Clinical Fellowship	Clinical Pharmacology and Experimental Therapeutics School of Medicine University of California, San Francisco (UCSF) Specialization: Neuropsychopharmacology, 09/2009-04/2012 Mentor: Leslie Floren, PHARMD
NIAAA Postdoctoral Fellowship	T-32 Postdoctoral Fellow Center for Alcoholism and Addiction Studies (CAAS) Brown University Specialization: Human Laboratory Studies, 09/2013-03/2016 Mentors: Robert Swift, MD, PHD and Lorenzo Leggio, MD, PHD

HONORS AND AWARDS

1994	Medal Italian Red Cross Commissioner International Association
1997	Medal Ministry of Defense, Italy for United Nation Mission in Somalia
2007	UCSF Drug Awareness Award, University of Utah, School on Alcoholism and Other Drug Dependencies, California Society of Health-Systems Pharmacists
2008	Research Creativity Award: Pathway Project Award Vince Isnardi, University of California, San Francisco
2009	Dean's Award for Outstanding Pharmaceutical Sciences Pathway Project Award, School of Pharmacy, University of California, San Francisco
2012	NIH/NIDA Travel Award Behavior, Biology, Chemistry: Translational Research Addiction, University Texas
2012	Postdoctoral Program for Excellence in Science, American Association for the Advancement of Science (AAAS)
2012	Strategic Opportunities Exploratory Award, UCSF
2012	JALA & JBS Art of Science Contest: <i>Science, religion and art all strive for their own answers...but all are alike in awe of the mysteries of life</i>
2013	Poster Award, European Society Biomedical Research Alcoholism (ESBRA), Warsaw, Poland
2013	Research Excellence Award, Center for Alcohol and Addiction Studies, Brown University
2014	NIH/NIAAA International Travel Award, Alcoholism and Stress: Framework for Future Treatment Strategies, Volterra, Italy
2015	NIH/NIAAA R13 International Travel Award, European Society Biomedical Research Alcoholism (ESBRA), Valencia, Spain
2016	New Investigator Award, American Society Clinical Psychopharmacology, Scottsdale, AZ
2017	Young Investigator Award Alcoholism and Stress: A Framework for Future Treatment Strategies. Translational models to investigate allosteric modulation as strategies for small molecules as first-generation alcohol use disorder therapeutics. Volterra, Italy
2017	Brown University, Faculty Travel Volterra, Italy
2017	Rohsenow Pilot Project Award, Center for Alcohol and Addiction Studies, Brown University
2017	NIDA-NIAAA Early Career Investigator Showcase (ECIS), Frontiers in Addiction Research, Washington, DC
2018	Dean's Award for Excellence in Research Collaboration, School of Public Health, Brown University
2018	NIAAA R13 International Travel Award, International Society Biomedical Research Alcoholism (ISBRA), Kyoto, Japan
2018	Brown University Faculty Travel Award Kyoto, Japan
2019	Travel Fellowship Winter Conference on Brain Research
2019	American College of Neuropsychopharmacology (ACNP), Travel Award, Orlando FL
2019	American College of Neuropsychopharmacology (ACNP), Elected to Associate Member
2022	Brown University, Board of Fellows, Master of Arts <i>ad eundem</i>

MILITARY SERVICE

1992 - 1996	Italian Red Cross, Auxiliary Military Italian Forces, Rome, Italy, Army Hospital, Celio, Orthopedic, Trauma and Emergency Medicine, Lieutenant Nurse
1993	United Nations Operation Somalia II (UNSOM II), Mogadishu, Johar, Emergency Field Nurse
1994 - 1995	Italian Air Force, Rome, Italy, Lieutenant in charge, Air Mobile Search and Rescue (S.A.R.)
1994	International Relief Missions, Rwanda, Emergency Field Nurse

1995 Mission Council of the Italian Government, Serbo-Bosnian War Emergency Field Nurse

ACADEMIC APPOINTMENTS

2013 - 2021 Bouvé College of Health Sciences, Northeastern University, Boston, MA Pharmacogenetics and Pharmacogenomics; Position: Lecturer

2015 - 2022 Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD; Position: Special Volunteer

2016 - 2017 Department of Psychiatry and Human Behaviors, Alpert Medical School, Brown University, Providence, RI; Position: Assistant Professor in Research track

2016 - 2017 Department of Behavioral and Social Sciences, School of Public Health, Brown University, Providence, RI; Position: Assistant Professor in Research track

2016 - 2017 Center for Alcohol and Addiction Studies, Brown University, Providence, RI; Position: Assistant Professor in Research track

2017 - 2021 Department of Psychiatry and Human Behaviors, Alpert Medical School, Brown University, Providence, RI; Position: Assistant Professor in Research Scholar track

2017 - 2021 Department of Behavioral and Social Science, School of Public, Brown University, Providence, RI; Position: Assistant Professor in Research Scholar track

2017 - 2021 Center for Alcohol and Addiction Studies, Brown University, Providence, RI; Position: Assistant Professor in Research Scholar track

2021 – pres. Department of Psychiatry and Human Behaviors, Alpert Medical School, Brown University, Providence, RI; Position: Associate Professor in Research Scholar track

2021 – pres. Department of Behavioral and Social Science, School of Public, Brown University, Providence, RI; Position: Associate Professor in Research Scholar track

2021 – pres. Center for Alcohol and Addiction Studies, Brown University, Providence, RI; Position: Associate Professor in Research Scholar track

2021 – pres. Carney Brain Institute for Brain Science, Brown University

HOSPITAL APPOINTMENTS AND CERTIFICATION

2007 - 2009 Department Public Health, Community Behavioral Health Services (CBHS), San Francisco General Hospital (SFGH), Drug Information Intern

2008 - 2009 UCSF Advanced Pharmacy Practice Experience

- UCSF Parnassus, General Medicine, Acute Care Inpatient
- SFGH, Anticoagulation Clinic, Family Health Clinic, Outpatient
- United States Coast Guard, Federal Pharmacy and Ambulatory Care

2009 - 2011 Medication Use and Safety Subcommittee (MUSS), San Francisco General Hospital (SFGH)

2014 Structured Clinical Interview (SCID) for DSM-IV and DMS-5 training, Butler Hospital

2015 - pres. Registered Phlebotomy Technician, Active certified member #2756154, American Medical Technologists

2018 - pres. Providence Veterans Affairs Medical Center, Without Compensation Appointment (WOC)

2019 Opioid Overdose Training, Opioid Response Network, SAMHSA

2021 NIH/CSR Certificate Eliminating Bias in peer review

SERVICE TO DEPARTMENT, CENTER, UNIVERSITY, HOSPITAL

UNIVERSITY COMMITTEES

- 2006 - 2007 California Society of Health-Systems Pharmacists, UCSF Drug Awareness Coordinator
- 2010 - 2012 Ernest Gallo Clinic and Research Center, UCSF Imaris Neuroscience microscopy/software interface, manager, administrator and technical support
- 2010 - 2012 Clinical Pharmacology and Experimental Therapeutics Fellowship Program, UCSF, Selection Committee
- 2016 - 2021 Department of Behavioral and Social Health Sciences, School of Public Health, Brown University, Providence, RI; Position: Master admissions committee
- 2017 - pres. Department of Behavioral and Social Health Sciences, School of Public Health, Brown University, Providence, RI; Doctoral Admissions Committee
- 2017 - pres. Rhode Island Department Health (RIDOH), Interagency on Overdose Research
- 2017 - pres. University La Sapienza Alcohol Center, Rome, Italy. US Advisory Board Member
- 2018 - pres. Brown University, Providence, RI; Institutional Review Board (IRB), Primary Member
- 2020 - 2022 Brown University, Providence, RI; School of Public Health Dean's Awards in Excellence in Research Collaboration, Recipient and Member
- 2020 - pres. Brown University, Providence, RI; Institutional Biosafety Committee (IBC), Member
- 2021 - pres. Neuroscience Graduate Program (NSGP), Brown University, Providence, RI; Doctoral NSGP Recruitment
- 2021 Brown University, Providence RI: Institutional Review Board (IRB) Subcommittee for Magnetic Resonance Imaging (MRI) Inform Consent Addendum
- 2022 - pres. Brown University, Providence, RI; Institutional Biosafety Committee (IBC), member of a subcommittee on the use of a replication incompetent SARS-CoV-2 model
- 2022 - pres. Brown University, Providence RI: Institutional Review Board (IRB) Subcommittee on Equity and the Recruitment of Non-English-Speaking Participants

REVIEWER FOR GRANT PROPOSAL

- 2016 - pres. European Foundation for Alcohol Research (ERAB) regular grant reviewer (annual review)
- 2017- 2020 National Institutes of Health (NIH), Center for Scientific Review (CSR), Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section (NPAS) *ad hoc* grant reviewer (tree meetings/year)
- 2017 Consortium Award peer review panel of the FY217 Alcohol and Substance Abuse Disorders Research Program (ASADRP) for the Department of Defense (DOD), Congressionally Directed Medical Research Programs (CDMRP), Scientific Reviewer
- 2018 NIH/National Institute Alcohol Abuse Alcoholism (NIAAA), Special Emphasis Panel, Opportunities for Collaborative Research at the Clinical Center (U01) ZAA1 DD (44), *ad hoc* grant reviewer
- 2018 NIH/CSR, Networks and Behavior in Psychiatric Disorders, *ad hoc* grant reviewer
- 2018 Université Catholique de Louvain, Belgium, Scientific reviewer
- 2018 NIH/CSR, Epigenomes and Connectomes in Psychiatric Disorders, *ad hoc* grant reviewer
- 2019 NIH/NIAAA, Special Emphasis Panel, Opportunities for Collaborative Research at the Clinical Center (U01) ZAA1 DD (11), RFA AA19-005 Medication Development, *ad hoc* grant reviewer
- 2020 NIH/NIAAA, Special Emphasis Panel NIAAA FRA AA-20-07 Medication Development for alcohol use disorder (AUD) and Alcohol-Related Organ Damage (AROD), *ad hoc* grant reviewer
- 2020 NIH/CSR, Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section (NPAS) Special Emphasis Panel/Scientific Review Group 2020/10 ZRG1 NPAS-W (07) S, *ad hoc* grant reviewer
- 2020 - 2022 NIH/CSR/NPAS, Standing Member
- 2021 NIH/NIAAA, ZAA1 GG (32) L NIAAA Individual Fellowships (F30, F31, F32) Review Panel

2021 Consortium Award peer review panel of the FY21 Alcohol and Substance Abuse Disorders Research Program (ASADRP) for the Department of Defense (DOD), Congressionally Directed Medical Research Programs (CDMRP), Scientific Reviewer

SOCIETY AND CONFERENCE RESPONSABILITIES

2018 - pres. International Society for Biomedical Research on Alcoholism (ISBRA), Member of the Education Committee

2019 - pres. Volterra Conference, Alcoholism and Stress: A Framework for future treatment strategies, Member of the Scientific Committee

2019 - pres. American College Neuropsychopharmacology (ACNP), Elected to Associate Member

2020 - 2023 American College Neuropsychopharmacology (ACNP), Member of the Program Committee

2021 - 2022 American College Neuropsychopharmacology (ACNP), Hot Topics/Data Blitz Subcommittee

2021 American College Neuropsychopharmacology (ACNP), Senior Scientists Engagement Task Force

EDITORIAL RESPONSABILITIES

2017 - 2020 Reviewer Editorial Board of Psychopharmacology, Frontiers in Psychiatry

2018 - 2019 Guest Editor, Special issue on "Translational Research in the Neurobiological Mechanisms of Alcohol and Substance Use Disorders. Neurotherapeutics, the official journal of the American Society for Experimental Neurotherapeutics

2019 - pres. Editorial Board of Alcohol and Alcoholism

REVIEWER RESPONSABILITIES (number peer reviewed manuscripts)

1. *Addictions* (N:2)
2. *Addiction Biology* (N: 7)
3. *Addictive Behaviors* (N: 2)
4. *Alcohol and Alcoholism* (N: 54)
5. *Alcoholism: Clinical and Experimental Research (ACER)* (N: 18)
6. *American Journal Addiction Medicine* (N: 2)
7. *American Psychology Association, Division 28, Psychopharmacology and Substance Abuse*
8. *American Psychology Association, Division 50 Addiction Psychology*
9. *Behavioral Brain Research* (N:1)
10. *Biological Psychiatry* (N: 9)
11. *Biological Psychology* (N: 2)
12. *Brain Behavior and Immunity* (N: 2)
13. *CNS Drugs* (N: 2)
14. *Current Psychopharmacology* (N: 2)
15. *Drugs* (N. 1)
16. *Drug and Alcohol Dependences* (N: 7)
17. *European Journal of Internal Medicine (EJIM)* (N: 4)
18. *Experimental and Clinical Psychopharmacology* (N: 1)
19. *Frontiers in Psychiatry, Endocrinology, Psychology* (N: 5)
20. *Journal of Neuroscience Research (JNR)* (N: 2)
21. *Journal of Studies on Alcohol and Drugs* (N: 1)
22. *Molecular Psychiatry* (N: 4)
23. *Nature* (N: 5)

24. *Nature Communications* (N: 1)
25. *Neuropharmacology* (N: 4)
26. *Neuropsychopharmacology* (N: 5)
27. *Neuropsychiatric Disease and Treatment* (N: 1)
28. *Neuroscience and Behavior Review* (N: 2)
29. *Neuroscience, Psychology and Psychiatry, Elsevier, Academic Press* (N: 1)
30. *Neurotherapeutics* (N: 5)
31. *PLOS ONE* (N: 4)
32. *Psychopharmacology* (N:2)
33. *Psychiatry Research* (N: 2)
34. *Psychoneuroendocrinology* (N: 10)
35. *Science, American Association Advancement of Science (AAAS)* (N: 4)
36. *Translational Psychiatry* (N.1)

MEMBERSHIP IN SOCIETIES

1. American Association for the Advancement of Science (AAAS)
2. American Association of Pharmaceutical Scientists (AAPS)
3. American College Neuropsychopharmacology (ACNP)
4. American Chemical Society (ACS)
5. American Pharmacists Association (APhA)
6. American Society Clinical Psychopharmacology (ASCP)
7. California Society of Health-Systems Pharmacists (CHSP)
8. International Society for Biomedical Research on Alcoholism (ISBRA)
9. Research Society for Alcoholism (RSA)
10. Society for Neuroscience (SfN)
11. Student National Pharmaceutical Association (SNPhA)

FDA INVESTIGATIONAL NEW DRUGS (IND)

1. IND 121984, mifepristone and yohimbine (active) – support for K01 AA23877
2. IND 135570, oxytocin and yohimbine (active) – support for P20 GM130414, K01 AA26874
3. IND 147824, probenecid (exempt) – support for R21 AA027614

PUBLICATION LIST

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS (*Mentee)

1. Simms JA, **Haass-Koffler CL**, Bito-Onon J and Bartlett SE. *Mifepristone in the Central Nucleus of the Amygdala Reduces Yohimbine Stress-Induced Reinstatement of Ethanol seeking.* Neuropsychopharmacology 2012. PMID: 22048462; PMCID: PMC3280651
2. **Haass-Koffler CL**, Naeemuddin M and Bartlett SE. *An Analytical Tool that Quantifies Cellular Morphology changes from Three-Dimensional Fluorescence Images.* Journal of Visualized Experiments 2012. PMID: 229551512; PMCID: PMC3486772 [VIDEO](#)
3. Chatterjee S, Santos N, Holgate J, **Haass-Koffler CL**, Hopf W, Kharazia V, Lester L, Bonci A and Bartlett SE. *The $\alpha 5$ Subunit Regulates the Expression and Function of $\alpha 4^*$ -Containing Neuronal Nicotinic Acetylcholine Receptors in the Ventral-Tegmental Area.* PLoS One 2013. PMID: 23869214; PMCID: PMC3712017

4. **Haass-Koffler CL** and Kenna GA. *Bacchus by Caravaggio as the visual diagnosis of Alcohol Use Disorder (AUD) from the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)*, Frontiers in Psychiatry 2013. PMID: 23964247; PMCID: PMC3737464. **Recipient: best performing articles in Frontiers**
5. Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Vuittonet C, Fricchione S, Brickley M, Beaucage K, **Haass-Koffler CL** and Leggio L. *Ondansetron reduces naturalistic drinking in non-treatment seeking alcohol dependent subjects with LL 5'-HTTLPR alleles: a laboratory study*. Alcoholism: Clinical and Experimental Research 2014. PMID: 24773166; PMCID: PMC4047179
6. Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Fricchione S, Brickley M, Beaucage K, **Haass-Koffler CL** and Leggio L. *Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: Exploratory findings*. Alcohol 2014. PMID: 25212749; PMCID: PMC4163011
7. Aoun EG, Lee MR, **Haass-Koffler CL**, Swift MR, Addolorato G, Kenna GA and Leggio L, *Relationship between the thyroid axis and alcohol craving*. Alcohol and Alcoholism 2014. PMID: 25433251; PMCID: PMC4266183
8. **Haass-Koffler CL**, Leggio L, Davidson D and Swift RM. *The Effect of Idazoxan on Human Alcohol Intoxication and Alcohol Pharmacokinetics*. Alcoholism: Clinical and Experimental Research 2015. PMID: 25833022; PMCID: PMC4384190
9. **Haass-Koffler CL**, Aoun EG, Kenna GA, de la Monte SM, Swift RM and Leggio L. *Exogenous intravenous ghrelin administration decreases leptin serum level and increases alcohol craving*. Translational Psychiatry, 2015. PMID: 26418274; PMCID: PMC5545639. **Selected Article: featured on the [NIDA Science Highlights](#)**
10. Kenna GA, **Haass-Koffler CL**, Zywiak WH, Edwards SM, Brickley MB, Swift RM and Leggio L. *Role of the alpha-1 Blocker Doxazosin in Alcohol Dependence: a Proof-of-Concept Randomized Double-Blind Placebo-Controlled Trial*. Addiction Biology 2016. PMID: 26037245; PMCID: PMC4668239
11. **Haass-Koffler CL**, *Giovenco DE, Lee MR, Zywiak WH, de la Monte SM, Kenna GA, Swift RM and Leggio L. *Serum insulin levels are reduced by intravenous ghrelin administration but do not correlate with alcohol craving in alcohol dependent individuals*, International Journal of Neuropsychopharmacology, 2016. PMID: 27207912; PMCID: PMC5091823
12. **Haass-Koffler CL**, Henry AT, Melkus G, Simms JA, Naemmuddin M, Nilsen CK, Schwandt ML, Hodgkinson CA, Magill M, Lasek AW, Momenam R, Bartlett SE, Swift RM, Bonci A, and Leggio L. *Defining the role of Corticotropin Releasing Factor Binding Protein in alcohol consumption*, Translational Psychiatry 2016. PMID: 27845775, PMCID: PMC3434418 **Recipient: New Investigator Award Volterra, Italy**
13. **Haass-Koffler CL**, *Goodyear K, Zywiak WH, Magill M, *Wallace PM, *Eltinge S, *Long VM, Jayaram-Lindström N, Swift RM, Kenna GA, Leggio. *Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin* Drug Alcohol Depend 2017. PMID: 28551590. PMCID: PMC5534374 **Selected Article in the New England Journal Medicine ([NEJM](#)) Journal Watch**
14. **Haass-Koffler CL**, *Goodyear K, *Long VM, Loche A, Cacciaglia R, Swift RM, and Leggio L. *Phase I randomized clinical trial for the safety, tolerability and pharmacokinetics of the mGluR5 negative allosteric modulator GET73 following single and repeated doses in healthy volunteers*, Eur J Pharm Sci 2017. PMID: 28778464; PMCID: PMC5776031
15. **Haass-Koffler CL**, *Goodyear K, *Long VM, *Tran HH, Loche A, Cacciaglia R, Swift RM, Leggio L, *Dataset for Phase I clinical trial for safety and tolerability of GET 73 in single and repeated doses including preliminary pharmacokinetics parameters*. Data in Brief, 2017. PMID: 29214202, PMCID: PMC5712048
16. *Aoun EG, Jimanez V, Vendruscolo LF, Walter NAR, Barbier E, Ferulli A, **Haass-Koffler CL**, Darakjian P, Lee, MR, Addolorato G, Heilig M, Hitzemann R, Koob GF, Grant KA, and Leggio L. *Relationship between the aldosterone - mineralocorticoid receptor pathway and alcohol drinking: preliminary translational findings across rats, monkeys and humans* Molecular Psychiatry 2018. PMID: 28461696 PMCID:

- PMC5668213 **Selected Article: featured on the NIAAA press release and selected as an NIH-wide press and Selected Article: NIDA paper of the month**
17. **Haass-Koffler CL**, *Goodyear K, Zywiak W, Kenna GA, Leggio L and Swift RM, *Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study*. Alcohol and Alcoholism, 2018. PMID: 29281033; PMCID: PMC5913672
 18. **Haass-Koffler CL**, *Goodyear K, Loche A, *Long VM, Cacciaglia R, Swift RM, and Leggio L. *Administration of the Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulator GET 73 With Alcohol: A Translational Study in Rats and Humans* Journal Psychopharmacology 2018. PMID: 29361897; PMCID: PMC7014573
 19. *Goodyear, K, **Haass-Koffler CL**, Chavanne D, Opioid use and stigma: the role of gender, language and precipitating events Drug and Alcohol Dependence 2018. PMID: 29499554; PMCID: PMC6097242
 20. **Haass-Koffler CL**, *Goodyear K, Zywiak W, Kenna GA, Leggio L and Swift RM, Corrigendum: *Aripiprazole and Topiramate on Free-Choice Alcohol Use* Alcohol and Alcoholism, 2018. PMID: 29718153; PMCID: PMC6016693
 21. **Haass-Koffler CL**, *Long VM, Farokhnia M, Magill M, Kenna GA, Swift RM and Leggio L. *Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: results from a double-blind, placebo-controlled human laboratory study* Neuropharmacology 2019. PMID:31310775; PMCID: PMC6745267 **Selected Article: presented by Dr. George Koob at the 152nd Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism**
 22. Tunstall BJ, Lorrai I, McConnell SA, Gazo KL, Zallar LJ, Di Guglielmo G, **Haass-Koffler CL**, Repunte-Canonigo V, Koob GF, Vendruscolo LF, Sanna PP. *Probenecid Reduces Alcohol Drinking in Rats: is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder?* Alcohol and Alcoholism 2019 PMID: 31535696; PMCID: PMC6751410
 23. **Haass-Koffler CL** and Schank JR, *Neurobiological Targets in Translational Addiction Research*, Editorial Use Disorders, Neurotherapeutics 2020 PMID: 31965552; PMCID: PMCID7007449
 24. **Haass-Koffler CL**. *Protein Tyrosine Phosphatase β/ζ and alcohol use disorder: A Commentary* Alcoholism: Clinical and Experimental Research 2020 PMID:32343842; PMCID: PMCID7486965
 25. **Haass-Koffler CL**, Piacentino D, Li X, *Long VM, Lee M, Kenna GA and Leggio L. *Differences in sociodemographic and alcohol-related clinical characteristics between treatment seekers and non-treatment seekers and their role in predicting outcomes in the COMBINE study for alcohol use disorder* Alcoholism: Clinical and Experimental Research 2020 PMID: 32997422; PMCID: PMCID7722230 **Selected Article: ACER Article of Public Interest (API)**
 26. *Portis S.M, **Haass-Koffler CL**. *New Microglial Mechanisms Revealed in Alcohol Use Disorder: How Does that Translate?* Invited Commentary Biological Psychiatry 2020 PMID:33213701; PMCID: PMCID7909747
 27. **Haass-Koffler CL**, *Perciballi R, *Brown Z, Zywiak WH, Lee M, Kurtis J, Swift RM, and Leggio L. *Relationship between cotinine levels and peripheral endogenous concentrations of oxytocin, β -endorphin and orexin in individuals with both alcohol and nicotine use disorders* The American Journal on Addictions 2021 PMID: 32488890; PMCID: PMCID7944578
 28. **Haass-Koffler CL**, *Souza RS, Wilmott J, Aston ER, Song JH. *A combined alcohol and smoking cue-reactivity paradigm in people who drink heavily and smoke cigarettes: preliminary findings* Alcohol and Alcoholism 2021 PMID: 32984874; PMCID: PMCID7768621 **Selected Article: Alcohol and Alcoholism Highlights issue 56-1 2021**
 29. Stopponi S, Fotio Y, Cifani C, Li H, **Haass-Koffler CL**, Cannella N, Demopoulos G, Gaitanaris G, Ciccocioppo R. *Andrographis paniculata and its main bioactive ingredient andrographolide decreases alcohol drinking and seeking in rats through activation of nuclear PPAR γ pathway* Alcohol and Alcoholism 2021 PMID: 33401299; PMCID: PMCID7906876; PMCID: PMCID7768621
 30. *Brown ZE, *Portis SM, *Vasaturo-Kolodner T, Fleig C, Swift RM, **Haass-Koffler CL**. *Randomized controlled trials for alcohol use disorder during the COVID-19 pandemic* Alcohol Invited editorial 2021 PMID: 33434615; PMCID: PMCID7832637

31. Farokhnia M, Abshire KM, Hammer A, Saravakumar A, Cobbina E, You ZB, **Haass-Koffler CL**, Lee MR, Akhlaghi F, Leggio L. *Neuroendocrine response to exogenous ghrelin administration, combined with alcohol, in heavy-drinking individuals: Findings from a randomized, double-blind, placebo-controlled human laboratory study* Int J Neuropsychopharmacology 2021. PMID: 33560411; PMCID: PMCID8278796 **Featured on the NIDA IRP website as the July 2021 Paper of the Month**
32. Zywiak, WH, **Haass-Koffler, CL**, Olinsky, A, Cavicchio, L, & Ciliberto, DJ. *Some Alcohol-Related Consequences for Women May Signal an Escape from Interpersonal Violence*. Special issue: Gender and Women's Studies and Health Care Advances in Applied Sociology 2021, 11, 177-184
33. *Goodyear Chavanne K, *Vasaturo-Kolodner T, Kenna GA, Swift RM, Leggio L and **Haass-Koffler CL** *Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for participants with alcohol use disorder*. The American Journal of Drug and Alcohol Abuse (AJDA) 2021 PMID: 34582281; PMCID: PMCID8711071
34. Monnig MA, Treloar Padovano H, Sokolovsky A, DeCost G, Aston E, **Haass-Koffler CL**, Szapary C, Moyo P, Avila J, Tidey J, Monti, PM, and Ahluwalia J. *Associations of Substance Use with Behavioral Adherence to CDC Guidelines for COVID-19 Mitigation* Journal of Medical Internet Research 2021 PMID: 34591780; PMCID: PMCID8582757
35. **Haass-Koffler CL**, *Perciballi R, Magill M, Loche A, Cacciaglia R, Leggio L. and Swift RM *An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder* Psychopharmacology 2021 PMID: 34731268; PMCID: PMCID8865311
36. Varodayan FP, Patel RR, Matzeu A, Wolfe SA, *Curley DE, Khom S, Gandhi P, Rodriguez L, Bajo M, D'Ambrosio S, Sun H, Kerr TM, Gonzales RA, Leggio L, Natividad LA, **Haass-Koffler CL**, Fardon M, Roberto M. *The amygdala noradrenergic system is compromised with alcohol use disorder* Biol Psychiatry 2022 PMID: 35430085; PMCID: PMCID9167785 **Selected Article: presented by Dr. George Koob at the 2022 Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism**
37. Lunerti V; Hongwu L; Benvenuti F; Shen Q; Domi A; Soverchia L; Di Martino RMC; Bottegoni G; **Haass-Koffler CL**, Cannella N. *The multitarget FAAH inhibitor/D3 partial agonist ARN15381 decreases nicotine self-administration in male rats*. Eur J Pharmacol 2022 PMID:35690082; PMCID:

OTHER PEER-REVIEWED PUBLICATIONS (*Mentee)

38. **Haass-Koffler CL** and Bartlett SE. *Stress and Addiction: Contribution of Corticotropin Releasing Factor System in Neuroplasticity*, Special Topic Frontiers, Frontiers In Molecular Neuroscience 2012. PMID: 22973190; PMCID: PMC3434418
39. **Haass-Koffler CL** Leggio L, and Kenna GA. *Pharmacological Approaches to Reducing Craving in Alcohol Use Disorders*, CNS Drugs 2014. PMID: 24573997; PMCID: PMC3990000
40. Vuittonet CL, Halse M, Leggio L, Fricchione S, Brickley M, **Haass-Koffler CL**, Tavares T, Swift RM and Kenna, GA. *Pharmacotherapy for Alcoholic Patients with Alcoholic Liver Disease*. American Journal of Health-System Pharmacy 2014. PMID: 25027533; PMCID: PMC4170837
41. **Haass-Koffler CL**, Akhlaghi, F, Swift RM, Leggio L. *Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?* Journal of Psychopharmacology 2017. PMID: 28093021; PMCID: PMC5768306
42. **Haass-Koffler CL**, Swift RM and Leggio L. *Noradrenergic targets in Alcohol Use Disorder, invited to contribute Special Issue focuses on Promising Alcohol Addiction Targets* Psychopharmacology, 2018. PMID:29460163; PMCID: PMC5995154
43. **Haass-Koffler CL**. *Role of Corticotropin Releasing Factor Binding Protein in the stress system: a strange case of Dr. Jekyll and Mr. Hyde? Invited Review as Young Investigator Awardee, Volterra Conference, Alcohol*, 2018 PMID: 29510883; PMCID: PMC5899053
44. *Goodyear Chavanne K and **Haass-Koffler CL** *Opioid craving in human laboratory settings: a review of the challenges and limitations*, Invited Review for Special Issue: Neurobiological Targets in Translational Addiction Research, Neurotherapeutics 2019 PMID: 31650431; PMCID: PMC7007448

45. **Haass-Koffler CL**, *Perciballi R. *Alcohol Tolerance in Human Laboratory Studies for Medications Development to treat Alcohol Use Disorder*, Alcohol and Alcoholism 2020 PMID: 31950152; PMCID: PMC7082491
46. **Haass-Koffler CL**, Cannella N and Ciccocioppo R. *Translational dynamics of alcohol tolerance between preclinical models and human laboratory studies*, Special Issue on: Advancing the Translation between Clinical and Preclinical Models of Individual Differences in Vulnerability to Substance Use Disorders, Experimental and Clinical Psychopharmacology 2020 PMID:32212746; PMCID: PMC7390637
47. *Curley DE, Webb A, Sheffler DJ, **Haass-Koffler, CL**. *Corticotropin releasing factor binding protein as a novel target to restore brain homeostasis: lessons learned from alcohol use disorder research*. Frontiers in Behavioral Neuroscience, section Motivation and Reward 2021 PMID: 34912198; PMCID: PMC8667027
48. *Curley DE, *Vasaturo-Kolodner T, Cannella N, Ciccocioppo R and **Haass-Koffler CL**. *Yohimbine as pharmacological probe for alcohol research: a systematic review in humans and rodents*. Neuropsychopharmacology 2022 PMID:35760866; PMCID:

BOOKS AND BOOK CHAPTERS

49. **Haass-Koffler CL** and McCance-Katz EF. Lowinson & Ruiz's (Eds), Substance Abuse: A Comprehensive Textbook, Fifth Edition, Section 7: Management of Associated Medical Conditions, 53: *Medication Interactions*. Lippincott Wilkins, 2011; JAMA 307(17):1868-1869. doi:10.1001/jama.307.17.1868 2012
50. **Haass-Koffler CL** and McCance-Katz EF. Principles of Addiction Medicine, 6th Edition, Chapter 8: *The Pharmacology of nonalcoholic Sedative Hypnotics*, American Society Addiction Medicine (ASAM) edited by Miller S, Rosenthal R, Fiellin D, and Saitz R, 2018
51. **Haass-Koffler CL** and McCance-Katz EF. Essentials of Addiction Medicine, 6th Edition, Chapter 8: *The Pharmacology of Nonalcoholic Sedative Hypnotics*, American Society Addiction Medicine (ASAM) edited by Miller S, Rosenthal R, Fiellin D, and Saitz R, 2019
52. McCance-Katz EF and **Haass-Koffler CL**. Principles of Addiction Medicine, 7th Edition, Section 2: Pharmacology, Chapter 10: *The Pharmacology of Nonalcoholic Sedative Hypnotics*, American Society Addiction Medicine (ASAM) edited by Miller S, Rosenthal R, Saitz R, Tetrult J, Levy S and Saxon A, (submitted, expected 2023)

NON-PEER REVIEWED PUBLICATIONS

53. **Haass-Koffler CL** and Gasper JJ. *Metabolic syndrome in patients treated with the second-generation antipsychotic*, Department Public Health, Community Behavioral Health Services, SFGH 2007
54. **Haass-Koffler CL**. *Formulary review: Angiotensin II Type 1 Receptor Antagonist*, Pharmacy & Therapeutics Committee, Department of Public Health, Laguna Honda Hospital 2008
55. **Haass-Koffler CL** and Gasper JJ. *Case Report: Pharmacokinetics of buprenorphine SL by alternative routes*, Department Public Health, Community Behavioral Health Services, SFGH 2008
56. **Haass-Koffler CL** and Gasper JJ. *Benzodiazepine withdrawal*, Department Public Health, Community Behavioral Health Services, SFGH 2008
57. **Haass-Koffler CL** and Gasper JJ. *Fentanyl TD tolerance*, Department Public Health, Community Behavioral Health Services, SFGH 2008
58. **Haass-Koffler CL** and Gasper JJ. *Drug-drug interaction between antiretroviral therapy and psychoactive drugs*, Department Public Health, Community Behavioral Health Services, SFGH 2008
59. **Haass-Koffler CL** and Gasper JJ. *Case report: Schizophrenia & varenicline (Chantix)*, Department Public Health, Community Behavioral Health Services, SFGH 2008
60. **Haass-Koffler CL** and Gasper JJ. *Stress and activation of κ -opioid*, Department Public Health, Community Behavioral Health Services, SFGH 2008
61. **Haass-Koffler CL** and Gasper JJ. *Clinical assessment of patients treated with clonazepam*, Department Public Health, Community Behavioral Health Services, SFGH 2008

62. **Haass-Koffler CL** and Gasper JJ. *Guidelines for physicians in psychiatric hospitals: Effectiveness, toxicity and drug interactions of psychotropic medications*, Department Public Health, Community Behavioral Health Services, SFGH 2009
63. **Haass-Koffler CL** and Leggio L. *Doxazosin: a new treatment for alcohol use disorder*. Editorial, Rivista di Alcologia: 31, 1, 2017, Firenze: Centro Alcologico Regionale Toscana, 2017
64. **Haass-Koffler CL**, *Perciballi R, *Brown ZE, Swift RM and Leggio L. *When clinical practice precedes clinical research: A case study of personalized addiction medicine* Editorial, Rivista di Alcologia: 41, 1, 2020, Firenze: Centro Alcologico Regionale Toscana, 2020
65. *Perciballi R and **Haass-Koffler CL**. *Il target noradrenico per lo sviluppo delle farmacoterapie per l'alcolismo*, Medicina delle Dipendenze Alcol: Nuove e vecchie frontiere (invited review), MDD 42, 2021

PATENTS AND PATENT APPLICATIONS (names in alphabetical order)

1. Bartlett SE, Bonci A, **Haass-Koffler CL**, Naeemuddin M. GC052P (61/166,632): *Chimera compositions and uses thereof* (filed April 3, 2009)
2. Bartlett SE, Bonci A, **Haass-Koffler CL**, Naeemuddin M. GC053P (61/243,437): *Ion channel compositions and uses thereof* (filed November 17, 2009)
3. Bartlett SE, Bonci A, **Haass-Koffler CL**, Naeemuddin M. GC054P (61/250,480): *Dedifferentiated cell compositions and uses thereof* (filed October 9, 2009)
4. Bartlett SE, Bonci A, **Haass-Koffler CL**, Naeemuddin M GC055P (61/261,981): *Assays for intracellular processes* (filed November 17, 2009)
5. **Haass-Koffler CL** (PCT/US2019/049498): *Composition and Methods for the Modulation of Corticotropin Releasing Factor Binding Protein and the treatment of Alcohol Use Disorder* (filed September 4, 2018, continuation March 18, 2022)

INTERVIEWS FOR MASS-MEDIA

- On the **BROWN DAILY HERALD**, the interview on the Award of the Center of Biomedical Research Excellence (COBRE) Award for the Center for Addiction and Disease Risk Exacerbation (CADRE): [\\$12.5 million grant funds new substance abuse research](#) by Emilia Sagaityte (published on September 2019)
- On the **INDY** (The College Hill Independent) the interview on rising of fentanyl crisis in the US: [The Rise of King Ivory, how fentanyl become one of the most lethal drug in America](#) by Gaya Gupta (published on November 2020)
- On **THE SCIENTIST**, the [Interview](#) by Marcus Banks on the article published on Nature Metabolism (March 2021): [Brain ethanol metabolism by astrocytic ALDH2 drives the behavioural effects of ethanol intoxication](#) by Jin, Yang, Zhu, Xu, Chen, Wang, Lin Cinar, Pawlosky, Zhang, Xiong, Gao, Koob, Lovinger and Zhang.
- On the **BROWN DAILY HERALD**, the interview by Anna Kim on the Office of the Vice President of Research (OVPR) Award: [2022 OVPR Seed Awards fund research by faculty](#) for the study: *Safety, feasibility, and acceptability of MDMA-assisted therapy for the treatment of co-occurring posttraumatic stress disorder and alcohol use disorders in combat veterans* (published on March, 2022)

NATIONAL ABSTRACTS PEER-REVIEWED

1. **Haass-Koffler CL**, Naeemuddin M, Nielsen CK, Bonci A, and Bartlett SE. *Corticotropin Releasing Factor Binding Protein in the CNS*, Gallo Center retreat, Asilomar, CA, 2009
2. **Haass-Koffler CL**, Naeemuddin M, Nielsen CK, Bonci A, and Bartlett SE. *Functional Expression of Corticotrophin Releasing Factor Binding Protein on cell surface*. Society of Neuroscience (SfN), San Diego, CA, 2010
3. Simms JA, **Haass-Koffler CL**, Richards JK, Kanholm I, Holgate JY, and Bartlett SE. *Mifepristone Decreases Yohimbine Stress-Induced Reinstatement of Ethanol Seeking Without Affecting Plasma Corticosterone Levels*. Society of Neuroscience (SfN), San Diego, CA, 2010

4. **Haass-Koffler CL**, Naeemuddin M, and Bartlett SE, *Quantification of F-actin Dynamics*, Gallo Center retreat, Headland Institute, CA, 2010
5. **Haass-Koffler, CL**, Naeemuddin M, and Bartlett SE. *Quantification of F-actin Dynamics*, 8th Advanced Imaging Methods Workshop, University California, Berkeley, CA, 2011
6. Milewski M, Gosalia P, LiY, Hedrick M, Hood R, Nguyen K, Suyama E, Vasile S, Sergienko E, Chun T, Cosford N, **Haass-Koffler CL**, Naeemuddin M, Nielsen CK, and Bartlett SE. *Utilization of a streamlined uHTS calcium mobilization assay to detect small molecule agonists and antagonists of the CRF-R2 receptor/CRF binding protein complex*. SLAS Symposium, San Diego, CA, 2011
7. Chatterjee S, Santos N, Holgate J, Henry A, **Haass-Koffler CL**, Hopf W, Kharazia V, Lester L, Bonci A, and Bartlett SE. *The $\alpha 5\alpha 4^*$ Neuronal Nicotinic Acetylcholine Receptor Plays an Important Role in Nicotine's Effect on Ethanol Consumption*. Gallo Center retreat, CA, 2011
8. **Haass-Koffler CL**, Naeemuddin M, Nielsen CK, Bonci A and Bartlett SE. *Functional Expression of Corticotrophin Releasing Factor Binding Protein on Cell Surface: From in vitro coverslip to Robotics, HTS optimization*. Gallo Center retreat, CA2011
9. **Haass-Koffler CL**, Chatterjee S, Naeemuddin M, Holgate JY, Kharazia, and Bartlett SE. *Three dimensional automated methods to quantify phenotypic differences in cell lines and dopaminergic neurons in the ventral tegmental area*. Accelerating Predictive Drug Development Through Quantitative Pharmacology Symposium. UCSF, Department of Bioengineering and Therapeutic Sciences, CA, 2011
10. Simms JA, **Haass-Koffler CL**, Richards JK, Kanholm, Holgate JY, and Bartlett SE. *Mifepristone Decreases Yohimbine Stress-Induced Reinstatement of Ethanol Seeking Without Affecting Plasma Corticosterone Levels*. Society for Neuroscience (SfN), Washington, DC, 2011
11. Chatterjee S, Santos N, Holgate JY, Henry AT, **Haass-Koffler CL**, Hopf FW, Kharazia V, Lester H, Bonci A, and Bartlett SE. *The $\alpha 5\alpha 4^*$ neuronal nicotinic acetylcholine receptor of the ventral tegmental area plays a key role for nicotine's effect on ethanol consumption*. Society for Neuroscience (SfN), Washington, DC, 2011
12. **Haass-Koffler CL**, Naeemuddin M, Nielsen CK, Bonci A, and Bartlett SE. *The C-Terminal Fragment of Corticotropin Releasing Factor Binding Protein (CRF-BP) potentiates CRF-Mediated CRF-Receptor 2 α (CRF-R2 α) Signaling*. Society for Neuroscience (SfN), Washington, DC, 2011
13. **Haass-Koffler CL**, Naeemuddin M, Henry AT, Nielsen CK, and Bartlett SE. *The C-Terminal Fragment of Corticotropin Releasing Factor Binding Protein (CRF-BP) potentiates CRF-Mediated CRF-Receptor 2 α (CRF-R2 α) Signaling*. Research Society of Alcoholism (RSA), San Francisco, CA, 2012, abstract in *Alcoholism: Clinical and Experimental Research*, 36 (Suppl. 2): 255A, 2012
14. **Haass-Koffler CL**, Henry AT, Kenna GA and Bartlett SE. *Altered binge-like ethanol consumption in corticotropin releasing factor binding protein-deficient mice*. Center Alcohol and Addiction Studies (CAAS) 30th year Celebration, Brown University, Providence, RI, 2013
15. Fricchione, S, Brickley, M, Zywiak, W, McGeary, J, Beaucage, K, Clifford, J, Shoaff, J, **Haass-Koffler, CL**, Swift, RM, Leggio, L, and Kenna, GA. *A Study Matching Serotonergic Drugs to LL vs SS/SL 5'-HTTLPR Alleles in Non-Treatment Seeking Alcohol Dependent Individuals*. 53rd Annual Meeting of the New England Conference on the Teaching of Psychology and the New England Psychological Association (NECTOP/NEPA), Bridgeport CT, 2013
16. Brickley, M, Fricchione, S, Leggio, L, Zywiak, W, McGeary, J, Swift, RM, Clifford, JS, Shoaff, J, Beaucage, K, **Haass-Koffler, CL**, and Kenna, GA. *Interaction on ondansetron and sertraline based on 5-HTTLPR and D4 alleles on drinking in non-treatment seeking alcohol dependent women*, 53rd Annual Meeting of the New England Conference on the Teaching of Psychology and the New England Psychological Association (NECTOP/NEPA), Bridgeport CT, 2013
17. Kenna GA, Zywiak WH, McGeary JE, Swift RM, Clifford JS, Shoaff J, Brickley M, Vuittonet C, Edwards C, Tavares T, Fricchione S, McGeary C, Beaucage K, **Haass-Koffler CL**, and Leggio L. *Personalized Treatment Matching of Serotonergics Based on 5'-HTTLPR and DRD4 in Non-Treatment-Seeking Alcoholics*. American College of Neuropsychopharmacology (ACNP), Hollywood, FL, 2013, Abstract in *Neuropsychopharmacology* 39 (Suppl. S1): S472, 2013

18. **Haass-Koffler CL**, McGeary JE, Davidson D, Kenna GA, Leggio L and Swift RM. *The Effect of Idazoxan on Human Alcohol Intoxication and Alcohol Pharmacokinetics*. Research Society of Alcoholism (RSA), Seattle, WA, 2014, Abstract Alcoholism: Clinical and Experimental Research, 38 (Suppl. S1): 48A, 2014
19. Aoun EG, **Haass-Koffler CL**, Swift RM, Addolorato G, Kenna GA, and Leggio L. *The Significance of Thyroid Hormones as Biomarkers for Prognosis and Baclofen Treatment Response in Alcohol Dependent Patients*, Mind Brain Research Day, Brown University, Providence, RI, 2014
20. Aoun EG, **Haass-Koffler CL**, Swift RM, Addolorato G, Kenna GA, and Leggio L. *The Significance of Thyroid Hormones as Biomarkers for Prognosis and Baclofen Treatment Response in Alcohol Dependent Patients*, American Psychiatric Association Annual Meeting, New York, NY, 2014
21. Aoun EG, **Haass-Koffler C**, Swift RM, Addolorato G, Kenna GA, and Leggio L. *The Role of Aldosterone and Cortisol in Alcohol Use Disorders in a Baclofen Treatment Study*. American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Hollywood, FL, 2014
22. Aoun EG, **Haass-Koffler CL**, Swift RM, Addolorato G, Kenna GA, and Leggio L. *The Role of Aldosterone and Cortisol in Alcohol Use Disorders in a Baclofen Treatment Study*, American Academy of Addiction Psychiatry (AAAP), Aventura, FL, 2014 **Recipient: 9th highest score out of 200 submission**
23. Kenna GA, Colombo GC, Zywiak WH, Caputo F, Swift RM, Addolorato G, Fricchione S, Brickley M, **Haass-Koffler CL**, L. Leggio. *Metadoxine for acute alcohol toxicity, alcoholism and alcoholic liver disease: preclinical and clinical findings*. Symposium presentation at the 2014 Research Society on Alcoholism (RSA) and International Society for Biomedical Research on Alcoholism (ISBRA) Joint Scientific Meeting, Bellevue, Washington. June 21-25, 2014; abstract in Alcoholism: Clinical and Experimental Research, 38 (Suppl. S1): 310A, 2014
24. Rauffenbart C, **Haass-Koffler CL**, Aoun EG, Kenna GA, de la Monte SM, Swift RM, and Leggio L. *Exogenous intravenous ghrelin administration decreases Leptin serum level and increases alcohol craving*. NIH/NIAAA Postbaccalaureate Poster Day, 2015
25. Le A, Kenna GA, **Haass-Koffler CL**, Zywiak WH, Edwards S, Brickley MR, Swift RM, Leggio L. Role of the $\alpha 1$ blocker doxazosin in alcoholism: A proof-of-concept randomized controlled trial. Poster presented at the NIH IRTA Postbac Poster Day 2015; Natcher Conference Center (Building 45), NIH main campus, Bethesda, MD. April 30, 2015
26. **Haass-Koffler CL**, Aoun EG, Kenna GA, de la Monte SM, Swift RM, and Leggio L. *Exogenous intravenous ghrelin administration decreases endogenous serum leptin level and increases alcohol craving*. Research Society of Alcoholism (RSA), San Antonio, TX, 2015
27. **Haass-Koffler CL**, Aoun EG, Kenna GA, de la Monte SM, Swift RM, and Leggio L. *Exogenous intravenous ghrelin administration decreases endogenous serum leptin level and increases alcohol craving*. American Academy of Addiction Psychiatry (AAAP), Huntington Beach, CA, 2015 abstract in American Journal on Addictions, 25(4): 310, 2016, **Selected: for Medscape Report**
28. **Haass-Koffler, CL**, DE Giovenco, PM Wallace, Henry AT, Melkus G, Simms JA, Naemmuddin M, Nielsen CK, Schwandt ML, Lasek A, Magill M, Momenam R, Hodgkinson CA, Bartlett SE, Swift RM, Bonci A, Leggio L. *In vitro, in vivo and human investigations on the role of Corticotropin Releasing Factor Binding Protein in alcohol consumption*, Mind Brain Research Brown University, Providence, RI, 2016
29. **Haass-Koffler CL**, DE Giovenco, PM Wallace, Zywiak, W, Kenna GA, de la Monte SM, Swift RM, and Leggio L *Ghrelin a Novel Possible Target to Treat Alcohol Craving and Role of Endogenous hormones Serum Levels as Biomarker*, Mind Brain Research Brown University, Providence, RI, 2016
30. **Haass-Koffler CL**, DE Giovenco, Wallace PM, Zywiak, W, Kenna GA, de la Monte SM, Swift RM, and Leggio L *Ghrelin a Novel Possible Target to Treat Alcohol Craving and Role of Endogenous hormones Serum Levels as Biomarker*, 56th American Society Clinical Psychopharmacology (ASCP), Scottsdale, AZ, 2016, **Selected: for Oral Presentation, ASCP New Investigator Award**
31. **Haass-Koffler, CL**, Henry AT, Melkus G, Simms JA, Naemmuddin, Nielsen CK, Schwandt ML, Lasek A, Magill M, Momenam R, Hodgkinson CA, Bartlett SE, Swift RM, Bonci A, Leggio L. *In vitro, in vivo and*

- human investigations on the role of Corticotropin Releasing Factor Binding Protein in alcohol consumption, Research Society of Alcoholism (RSA), New Orleans, LA, 2016 abstract in Alcoholism: Clinical and Experimental Research, 40 (Suppl. S1), 139A
32. **Haass-Koffler CL**, Giovenco D, Zywiak, W, Kenna GA, de la Monte SM, Swift RM, and Leggio L. *Endogenous Intravenous Ghrelin Administration Decreases Endogenous Insulin and Increased Alcohol Craving*, Research Society of Alcoholism (RSA), New Orleans, LA, 2016, abstract in Alcoholism: Clinical and Experimental Research, 40 (Suppl. S1), 139A
 33. **Haass-Koffler CL**, Giovenco D, Zywiak WH, McGeary J, Kenna GA, de la Monte SM, Leggio L, Swift RM L. *Aripiprazole and Topiramate on Free-Choice Alcohol Use and Exploratory Pharmacogenetics*, Research Society of Alcoholism (RSA), New Orleans, LA, 2016, abstract in Alcoholism: Clinical and Experimental Research, 40 (Suppl. S1), 139A
 34. Wallace PR, **Haass-Koffler CL**, Goodyear K, Zywiak WH, Magill M, Eltinge S, Jayaram-Lindström N, Swift RM, Kenna GA, Leggio. *Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin*. Warren Alpert Medical School Summer Showcase, Brown University, Providence RI, November 2016
 35. **Haass-Koffler, CL**, Henry AT, Melkus G, Simms JA, Naemmuddin, Nielsen CK, Schwandt ML, Lasek A, Magill M, Momenam R, Hodgkinson CA, Bartlett SE, Swift RM, Bonci A, Leggio L. *In vitro, in vivo and human investigations on the role of Corticotropin Releasing Factor Binding Protein in alcohol consumption*, 55th American College on Neuropsychopharmacology (ACNP), Hollywood, FL, 2016, abstract in Neuropsychopharmacology 41 (S1): S629, 2016
 36. Eltinge SE, Goodyear K, Chavanne D, Wallace PM, Long VM, Swift RM, Leggio L and **Haass-Koffler CL**. *Demand inelasticity and higher demand intensity on the Alcohol Purchase Task is associated with greater reduction in drinking in patients with Alcohol Use Disorder*, Mind Brain Research Day, Brown University, Providence, RI, 2017
 37. Long VM, Goodyear K, Loche L, Cacciaglia R, Swift RM, Leggio L and **Haass-Koffler CL**,. *Safety, tolerability and pharmacokinetics of the mGluR5 negative allosteric modulator GET73 following single and repeated doses in healthy volunteers*. Mind Brain Research Day, Brown University, Providence, RI, 2017
 38. Long VM, Goodyear K, Loche L, Cacciaglia R, Swift RM, Leggio L and **Haass-Koffler CL**, *A phase 1 randomized cross-over drug-alcohol interaction study with the mGluR5 negative allosteric modulator GET 73 in healthy male volunteers*. Mind Brain Research Day, Brown University, Providence, RI, 2017
 39. Long VM, Goodyear K, Loche L, Cacciaglia R, Swift RM, Leggio L and **Haass-Koffler CL**, *A phase 1 randomized cross-over drug-alcohol interaction study with the mGluR5 negative allosteric modulator GET 73 in healthy male volunteers*. School of Public Health Research Day, Brown University, Providence, RI, 2017
 40. **Haass-Koffler CL**, Goodyear K, Eltinge SE, Wallace PM, Long VM, Cacciaglia R, Swift RM, Leggio L. *Safety, tolerability, pharmacokinetics and bioavailability of GET73 and its metabolite MET2*. Research Society of Alcoholism (RSA), Denver, CO, 2017 abstract in Alcoholism: Clinical and Experimental Research, 41 (Suppl. S1), 218A, 2017
 41. Goodyear K, **Haass-Koffler CL**, Eltinge SE, Chavanne D, Wallace PM, Long VM, Swift RM, Leggio L. *Intensity of Alcohol Demand as a Moderator of Alcohol Drinking in Alcohol-Dependent Individuals Treated with Doxazosin*. Research Society of Alcoholism (RSA), Denver, CO, 2017, 2017 abstract in Alcoholism: Clinical and Experimental Research, 41 (Suppl. S1), 218A, 2017
 42. **Haass-Koffler CL**, Leggio L, Swift RM. *The $\alpha 1$ blockade by doxazosin in regulation of alcohol drinking in alcohol-dependent patients*. Symposium presentation at the 2017 Research Society on Alcoholism (RSA), Denver, CO. June 24-28, 2017; abstract in Alcoholism: Clinical and Experimental Research, 41 (Suppl. S1), 296A, 2017
 43. Tran HH, Goodyear K, Farokhnia M, Swift RM, Leggio L and **Haass-Koffler CL**, *Analysis of endogenous hormones in alcoholic smokers*, Brown University, Providence, RI, Summer Research Symposium, 2017

44. **Haass-Koffler CL**, Francis CT, Sheffer DJ, Naemmuddin M, Nilsen CK, Bartlett SE, Swift RM, Leggio L, N Cosford NDP and Bonci A. *Development of Corticotropin Releasing Factor Binding Protein allosteric modulators*. 56th American College on Neuropsychopharmacology (ACNP), Palm Spring, CA 2017, Neuropsychopharmacology 43 (S1): S456, 2017
45. Swift RM, **Haass-Koffler CL**, Leggio L, Cacciaglia R. *A Human Laboratory Study of the mGluR5 Modulator GET 73 on Alcohol Pharmacokinetics and Pharmacodynamics and Alcohol Craving*, 56th American College on Neuropsychopharmacology (ACNP), Palm Spring, CA 2017 abstract in Neuropsychopharmacology 43 (S1): S456, 2017
46. **Haass-Koffler CL**, Francis CT, Sheffer DJ, Naemmuddin M, Nilsen CK, Bartlett SE, Swift RM, Leggio L, N Cosford NDP and Bonci A. *Development of Corticotropin Releasing Factor Binding Protein allosteric modulators*. Gordon Conference, Galveston, TX 2018
47. Souza RD, Wilmott J, Long VM, Goodyear K, Magill M, Swift RM, Song JH, **Haass-Koffler CL**. *Integrated cue-reactivity paradigm to asses selective attention to simultaneous alcohol and smoking cues: a pilot study*. Mind Brain Research Day Brown University, RI 2018
48. Long VM, Goodyear K, Swift RM, Leggio L and **Haass-Koffler CL**, *Ghrelin effects on endogenous serum cortisol and aldosterone levels in alcohol dependent individuals*. Mind Brain Research Day Brown University, RI 2018
49. Tran HH, Long VM, Goodyear K, Leggio L, **Haass-Koffler CL**. *Preliminary analysis for correlation between oxytocin, endogenous stress hormones and opioid hormone in alcoholic smokers*. Mind Brain Research Day Brown University, RI 2018
50. Wilmott J, Souza RD, Song JH, **Haass-Koffler CL** *Selective attention predicts choice behavior in heavy drinking smokers*. School Public Health, Research Day Brown University, RI 2018 **Recipient: Dean's Award for Excellence in Research Collaboration, School Public Health, Brown University**
51. Souza RD, Wilmott J, Long VM, Goodyear K, Magill M, Swift RM, Song JH, **Haass-Koffler CL**. *Integrated cue-reactivity paradigm to asses selective attention to simultaneous alcohol and smoking cues: a pilot study*. School Public Health, Research Day Brown University, RI 2018 **Recipient: Dean's Award for Excellence in Research Collaboration, School Public Health, Brown University**
52. Tran HH, Long VM, Goodyear K, Leggio L, **Haass-Koffler CL**. *Preliminary analysis for correlation between oxytocin, endogenous stress hormones and opioid hormone in alcoholic smokers*. School Public Health, Research Day Brown University, RI 2018
53. Souza RD, Wilmott J, Long VM, Goodyear K, Magill M, Swift RM, Song JH, **Haass-Koffler CL**. *Integrated cue-reactivity paradigm to asses selective attention to simultaneous alcohol and smoking cues: a pilot study*. RSA, San Diego, CA, 2018, abstract in Alcoholism: Clinical and Experimental Research, 42 (Suppl. S1), 72A, 2018, **Recipient: Student Merit Award**
54. Long VM, Goodyear K, Swift RM, Leggio L and **Haass-Koffler CL**, *Ghrelin effects on endogenous serum cortisol and aldosterone levels in alcohol dependent individuals*. Research Society for Alcoholism (RSA), San Diego, CA, 2018, abstract in Alcoholism: Clinical and Experimental Research, 42 (Suppl. S1), 72A, 2018
55. Goodyear K, Chavanne D, Long VM, Souza RD, Swift RM, Leggio L, **Haass-Koffler CL**. *Substance use and stigmatizing attitudes*. Poster presented at the 2018 Research Society on Alcoholism (RSA), San Diego, CA. June 16-20, 2018; abstract in Alcoholism: Clinical and Experimental Research, 42 (Suppl. S1), 72A, 2018
56. **Haass-Koffler CL**, Swift RM, and Leggio L. *Intravenous Administration of Ghrelin Increases Blood Cortisol and Aldosterone Concentrations in Heavy-Drinking Alcohol-Dependent Individuals: Results from a Double-Blind Placebo-Controlled Human Laboratory Study*. 57th American College on Neuropsychopharmacology (ACNP), Hollywood, FL 2018, abstract in Neuropsychopharmacology 43 (S1): S139, 2018
57. **Haass-Koffler CL**, Long VM, Farokhnia M, Kenna GA, Swift RM, Leggio L. *Intravenous administration of ghrelin increases blood cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind placebo-controlled human laboratory study*. Poster presented at

- the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL. December 8-13, 2017; abstract in *Neuropsychopharmacology* 43 (S1): S139, 2018
58. Souza RS, Willmott J, Long VM, Goodyear K, Son J, Swift RM, Magill M, Aston E, **Haass-Koffler CL**. *Integrated Cue-Reactivity Paradigm to Assess Selective Attention to Simultaneous Alcohol and Smoking Cues: A Pilot Human Laboratory Study*. Mind Brain Research Day/Public Health Research Day, Brown University, Providence, RI, 2019
 59. Perciballi R, Persaud B, Leggio L, and **Haass-Koffler CL**, *Effects of smoking on endogenous hormones in individuals with alcohol use disorder*. Mind Brain Research Day/Public Health Research Day, Brown University, Providence, RI, 2019
 60. Long VM, Farokhnia M, Magill M, Kenna GA, Swift RM, Leggio L, **Haass-Koffler CL**. *Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: results from a double-blind, placebo-controlled human laboratory study*. Mind and Brain Research Day, Brown University, Providence RI, 2019.
 61. Persaud B, Perciballi R, Leggio, L, and **Haass-Koffler CL**, *Effects of smoking on endogenous hormones in individuals with alcohol use disorder*. Public Health Research Day, Brown University, Providence, RI, 2019
 62. Goodyear K, Swift RM, Leggio L and **Haass-Koffler CL**, *Neural responses to alcohol cues in heavy-drinking smokers*. Mind Brain Research Day, Brown University, Providence, RI, 2019. **Recipient Best Postdoc Poster, 1st prize**
 63. Long VM, Piacentino D, Li X, Leggio L, **Haass-Koffler CL**. *Comparing non-treatment-seeking participants in alcohol medication research studies across demographic and clinical variables by geographic location*. School of Public Health Research Day, Brown University, Providence RI, 2019
 64. Perciballi R, Ceccanti N; Attilia ML; Swift RM and **Haass-Koffler CL** *Case report: "If...you hear hoof beats behind you, don't look back expecting to see a zebra. Expect a horse" (Theodore Woodward). The horse case: Alcohol Use Disorder (AUD) and Dilated Cardiomyopathy (DCM)*. Public Health Research Day, Brown University, Providence, RI, 2019
 65. Goodyear K, Swift RM, Leggio L and **Haass-Koffler CL**, *Neural responses to alcohol cues in heavy-drinking smokers*. Public Health Research Day, Brown University, Providence, RI, 2019
 66. **Haass-Koffler CL**, Swift RM, and Leggio L. *Intravenous Administration of Ghrelin Increases Blood Cortisol and Aldosterone Concentrations in Heavy-Drinking Alcohol-Dependent Individuals: Results From a Double-Blind Placebo-Controlled Human Laboratory Study*. Research Society for Alcoholism (RSA), Minneapolis, MN, 2019, abstract published in Alcoholism: Clinical and Experimental Research Journal, 43 (Suppl. S1), 224A, 2019
 67. Goodyear K, Swift RM, Leggio L and **Haass-Koffler CL**, *Neural responses to alcohol cues in heavy-drinking smokers*. 4th International Conference on Applications of Neuroimaging to Alcoholism (ICANA-4) Yale University, New Haven, CT, 2019
 68. **Haass-Koffler CL**, Piacentino D, Long VM, Li X, Lee M, Kenna GA, Swift RM, Leggio L. *Demographic and clinical differences between treatment-seeking and non-treatment-seeking participants in medication studies to treat alcohol use disorder*. Poster presented at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Orlando, FL. December 8-11, 2019; abstract in Neuropsychopharmacology 44(Suppl. S1), S256, 2019
 69. Swift RM, **Haass-Koffler CL**, Leggio L, Cacciaglia R. *A Study of the mGluR5 modulator get 73 on alcohol pharmacokinetics and pharmacodynamics in non-treatment seeking alcohol dependent individuals*. Poster presented at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Orlando, FL. December 8-11, 2019; abstract in Neuropsychopharmacology 44(Suppl. S1), S222, 2019
 70. *Brown ZE, Piacentino D, *Perciballi R, Li X, Long VM, Swift RM, Leggio L, **Haass-Koffler CL**. *Treatment-seeking versus non-treatment-seeking research participants in predicting the outcome of alcohol use disorder treatments: The role of their sociodemographic and alcohol-related characteristics*. Public Health Research Day, Brown University, Providence, RI, April 6, 2020, *Virtual due to COVID-19 pandemic*

71. *Portis S, *Gonsavales M, Portis S, Brown ZE, Vasaturo-Kolodner T, Ferretti A, Fleig C, Mc Geary J, Zywiak WH, Leggio L, White T, **Haass-Koffler CL**, *Characterization of Alpha-1 Receptors Expression in Individuals with Alcohol Use Disorder*. Poster presented at the 59th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), December 2020 *Virtual due to COVID-19 pandemic*
72. *Munivar, A., **Haass-Koffler, CL**, Wu, Kenna GA, R., O'Malley SS, Leggio, L. *Metadoxine Reduces Alcohol Consumption in a Double-Blind, Placebo-Controlled, Pilot Study in Patients with Alcohol Use Disorder*. Poster presented at the 59th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), December 2020, *Virtual due to COVID-19 pandemic*
73. *Goodyear K, *Vasaturo-Kolodner T, Leggio L, Kenna GA, Swift RM and **Haass-Koffler CL**. *Changes in alcohol-related behaviors and characteristics from the baseline to the randomization session for participants with alcohol use disorder*. School of Public Health Research Day, Brown University, April 2021
74. *Curley DE, *Brown ZE, *Vasaturo-Kolodner T, Cannella N, Swift RM, Ciccocioppo R and **Haass-Koffler CL**. *Sex difference in the effect of yohimbine on alcohol-related behaviors* School of Public Health Research Day, Brown University, April 2021
75. *Portis SM, Sun H, Leggio L and **Haass-Koffler CL**. *Increased amygdala expression of receptors alpha-1B in postmortem brain of individuals with alcohol use disorder*. School of Public Health Research Day, Brown University, April 2021
76. *Ferretti A, *Curley DE, *Portis SM, *Quintana A, *Brown ZE, Fleig C, Swift RM and **Haass-Koffler CL**. *The impact of COVID-19 pandemic on alcohol-related behaviors in individual with Alcohol Use Disorder*. School of Public Health Research Day, Brown University, April 2021
77. Monnig, MA, Treloar Padovano, H, Sokolovsky, A, DeCost, G, Aston, E, **Haass-Koffler, CL**, Szapary, C, Tidey, J, Monti, PM, and Ahluwalia J. *Alcohol and Opioid use are associated with adherence to CDC Guidelines to reduce the spread of COVID-19*. Research Society for Alcoholism (RSA), San Antonio, 2021
78. Zhang Q, Benvenuti F, Borruto AM, Bianchin G, Li H, **Haass-Koffler CL**, Ciccocioppo R, Cannella N. *The pharmacological stressor yohimbine differently affect alcohol seeking in genetical selected Marchigian Sardinian alcohol preferring and non-selected Wistar rats*. Research Society for Alcoholism (RSA), San Antonio, TX, 2021
79. *Goodyear K, *Vasaturo-Kolodner T, Leggio L, Kenna GA, Swift RM and **Haass-Koffler CL**. *What is the true baseline session? A comparison of changes in alcohol-related characteristics from screening to randomization in treatment and non-treatment seekers*. Research Society for Alcoholism (RSA), San Antonio, TX, 2021
80. *Curley DE, *Brown ZE, *Vasaturo-Kolodner T, Cannella N, Swift RM, Ciccocioppo R and **Haass-Koffler CL**. *Sex difference in the effect of yohimbine on alcohol-related behaviors*. Research Society for Alcoholism (RSA), San Antonio, TX, 2021
81. *Portis SM, Sun H, Leggio L and **Haass-Koffler CL**. *Increased amygdala expression of receptors alpha-1B in postmortem brain of individuals with alcohol use disorder*. Research Society for Alcoholism (RSA), San Antonio, TX, 2021
82. **Haass-Koffler CL**, *Perciballi R, Magill M, Colombo GC, Loche A, Cacciaglia R, Swift RM, and Leggio L. *Alcohol-drug interaction studies from preclinical to human laboratory studies: evaluation of a metabotropic glutamate receptor subtype 5 (mGluR5) as a pharmacotherapy for Alcohol Use Disorder* Poster submitted to the 60th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Porto Rico. December 8-11, 2021
83. Nelson MJ, Soliman P, Rhew R, **Haass-Koffler CL**, *Disruption of Circadian Rhythms Promotes Alcohol Use*. School of Public Health Research Day, Brown University, April 2022

INTERNATIONAL ABSTRACTS PEER-REVIEWED

84. **Haass-Koffler CL**, Kenna GA, Simms JA and Bartlett SE. *Mifepristone Reduces Stress-Induced Reinstatement of Ethanol-Seeking*. European Society for Biomedical Research on Alcoholism (ESBRA),

- Warsaw, Poland, 2013; abstract in Alcohol and Alcoholism, 48(Suppl. 1): i4, 2013, **Recipient: ESBRA Best Poster Award**
85. **Haass-Koffler CL**, Kenna GA, Henry AT and Bartlett SE. *Altered binge-like ethanol consumption in corticotropin releasing factor binding protein-deficient mice*, European Society for Biomedical Research on Alcoholism (ESBRA), Warsaw, Poland, 2013, abstract in Alcohol and Alcoholism, 48(Suppl. 1): i4, 2013
 86. Kenna GA, Zywiak WH, McGeary JE, Swift RM, Clifford JS, Shoaff J, Brickley M, Vuittonet C, Edwards C, Tavares T, Fricchione S, McGeary C, Beaucage K, **Haass-Koffler CL**, and Leggio L. *Personalized Treatment Matching of Serotonergic Based on 5'-HTTLPR and DRD4 in Non-Treatment-Seeking Alcoholics*. European Society for Biomedical Research on Alcoholism (ESBRA), Warsaw, Poland, 2013, abstract in Alcohol and Alcoholism, 48(Suppl. 1): i4, 2013
 87. **Haass-Koffler CL**, Simms JA, Kenna GA, Leggio L and Bartlett SE. *Yohimbine induces acute stress response and assesses of the specific effect of mifepristone in ethanol self-administration*. Alcoholism and Stress: A Framework for Future Treatment Strategies. Volterra, Italy, 2014 **Recipient: NIH/NIAAA International Travel Award**
 88. Farokhina M, **Haass-Koffler CL**, Zywiak W, Swift RM, Kenna GA, and Leggio L. *Role of the alpha-1 blocker doxazosin in alcoholism: effect limited to patients with positive family history of alcoholism*, Society of biological Psychiatry, Toronto, Ontario, Canada, 2015
 89. **Haass-Koffler CL**, Aoun EG, Kenna GA, de la Monte SM, Swift RM, and Leggio L. *Exogenous intravenous ghrelin administration decreases endogenous serum leptin level and increases alcohol craving*. European Society for Biomedical Research on Alcoholism (ESBRA), Valencia, Spain, 2015, abstract in Alcohol and Alcoholism, 50(Suppl. 1): i56, 2015 **Recipient: NIH/NIAAA International Travel Award**
 90. Kenna GA, **Haass-Koffler CL**, Zywiak W, Swift RM, and Leggio L. *Role of the alpha-1 blocker doxazosin in alcoholism: effect limited to patients with positive family history of alcoholism*, European Society for Biomedical Research on Alcoholism (ESBRA), Valencia, Spain, 2015, abstract in Alcohol and Alcoholism, 50(Suppl. 1): i67, 2015
 91. Farokhnia M, **Haass-Koffler CL**, Zywiak WH, Swift RM, Kenna GA, Leggio L. *Noradrenergic system as a pharmacological target for alcoholism: A randomized, double-blind, placebo-controlled, proof-of-concept, clinical trial with doxazosin*. Poster presented at the Society of Biological Psychiatry (SOBP) 70th annual meeting, Toronto, Canada. May 14-16, 2015; abstract in Biological Psychiatry. 2015;77(9): S177
 92. Goodyear K, **Haass-Koffler CL**, Zywiak WH, Magill M, Wallace PR, Eltinge S, Jayaram-Lindström N, Swift RM, Kenna GA, Leggio. *Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin*. Alcoholism and Stress: A Framework for Future Treatment Strategies, Volterra, Italy, 2017 abstract in Alcohol, 60 (P119): 222-223, 2017
 93. **Haass-Koffler CL**, *Translational models to investigate allosteric modulation as strategy for small molecules as first-generation alcohol use disorder therapeutics*. Volterra, Italy, May, abstract in Alcohol, 60 (Y84): 231, 2017 **Recipient: Volterra New Investigator Award**
 94. **Haass-Koffler CL**, Souza RD, Wilmott J, Long VM, Goodyear K, Magill M, Song JH, Swift RM. *Integrated cue-reactivity paradigm and eye-tracking paradigm to asses selective behavior and selective attention to simultaneous alcohol and smoking cues*. International Society for Biomedical Research on Alcoholism (ISBRA), Kyoto, Japan, 2018 **Recipient: NIH/NIAAA International Travel Award and Brown University Faculty Travel Award**
 95. Perciballi R, Long VM, Piacentino D, Li X, Leggio L, **Haass-Koffler CL**. *Comparing non-treatment-seeking participants in alcohol medication research studies across demographic and clinical variables by geographic location*. European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France, 2019, abstract in Alcoologie et Addictologie, 41 (3): 378, 2019

96. Persaud, B, Perciballi, R, Leggio, L, and **Haass-Koffler CL**, *Effects of smoking on endogenous hormones in individuals with alcohol use disorder*. European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France, 2019, abstract in Alcoologie et Addictologie, 41 (3): 378, 2019
97. Goodyear K, Swift RM, Leggio L and **Haass-Koffler CL**, *Neural responses to alcohol cues in heavy-drinking smokers*. European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France, 2019, abstract in Alcoologie et Addictologie, 41 (3): 378, 2019

INVITED NATIONAL PRESENTATIONS AND SYMPOSIA

1. *Abuse of prescription drugs*, Walgreen's Pharmacy, Daily City, CA, 2006
2. *Corticotropin Releasing Factor Binding Protein in the CNS*, UCSF Pharmaceutical Sciences Pathway Project presentation, 2009
3. *Corticotropin Releasing Factor Binding Protein in the CNS*, UCSF, School of Medicine, Clinical Pharmacology and Experimental Therapeutic, Quarterly Research Seminars, 2010
4. *In vivo Microscopy: applications in Neuroscience*, Gallo Center workshop, Headland Institute, CA, 2010
5. *Too Busy To Live, Role of Schedules and Stress, Stroke and Cardiovascular Disease*, Health Now Forum, Mill Valley, CA, 2010
6. *A novel approach to characterize the role of Corticotropin Releasing Factor Binding Protein in the CNS*, Gallo Center data presentation, 2010
7. *Molecular Characterization of Corticotropin Releasing Factor-Binding Protein*. Clinical Pharmacology and Experimental Therapeutics Fellows' Quarterly Research Seminar, 2011
8. *Molecular Characterization of Corticotropin Releasing Factor-Binding Protein*. Gallo Center data presentation, 2011
9. *The C-Terminal Fragment of Corticotropin Releasing Factor Binding Protein (CRF-BP) potentiates CRF-Mediated CRF-Receptor 2 α (CRF-R2 α) signaling*. Behavior, Biology, Chemistry: Translational Research in Addiction, University of Texas, Health Center, San Antonio, TX, 2012 **Recipient: NIH/NIDA Travel Award**
10. *Novel Method to interrogate Corticotropin Releasing Factor Binding Protein (CRFBP) in the CNS*. Tufts University, Behavioral Core Neuroscience Research Center, Medford, MA, 2012
11. *Stress as Discrete Biobehavioral Approach in Alcohol Use Disorder*. Knowledgebase, CAAS, Brown University, Providence, RI, 2013
12. *Pharmacological treatments for alcoholism: recent translational and clinical findings*, NIH, NIAAA and NIDA, Clinical Center, Bethesda, MD, 2015
13. *Pharmacological treatments for alcoholism: recent translational and clinical findings* UCONN Health, Alcohol Research Center, University of Connecticut, Farmington, CT, 2015
14. Symposium: *On the role of feeding peptides in alcoholism: recent clinical findings. Part of the symposium: Going with Your Gut: Appetitive Hormones and the Regulation of Substance Use*, American College on Neuropsychopharmacology (ACNP) Hollywood, FL, December, 2015; abstract in Neuropsychopharmacology 40 (S1): S397, 2015 (Invited speaker)
15. Oral Communication: *Ghrelin as a novel possible target to treat alcohol craving and role of endogenous serum levels as biomarker*. American Society of Clinical Psychopharmacology (ASCP), Scottsdale, AZ, June 2016 **Recipient: ASCP New Investigator Award**
16. Presentation: *Mifepristone As A Pharmacological Intervention For Stress-Induced Alcohol Drinking*, Corcept Therapeutics Research Conference, San Francisco, CA November 2016 (Invited speaker)
17. Symposium: *Neuropsychoenocrine pathways in addiction*, American Association Addiction Psychiatry (AAP), Coconut Grove, FL December 2016; abstract in American Journal on Addictions, 25(4): 310, 2016 (invited speaker)
18. Session-III Mini-Convention: *Novel Approaches for Translational Research and Drug Discovery*. Society for Neuroscience, Washington, DC, **Recipient: NIDA-NIAAA, Early Career Investigator Showcase**

19. Individual Presentation: *Expression of the functional C-terminus of Corticotropin Releasing Factor Binding Protein on the cell surface that enables a novel cell-based high-throughput screening assay* Sanford Burnham Prebys Medical Discovery Institute February 2018 (invited speaker)
20. Symposium: *Noradrenergic mechanisms at the intersection of alcohol dependence and stress* Research Society for Alcoholism (RSA), San Diego, CA, June 2018, abstract in Alcoholism: Clinical and Experimental Research, 42 (Suppl. S1), 72A, 2018 (discussant)
21. Symposium: *CRFR2 and CRFBP in CRF-induced potentiation of NMDR transmission in the VTA* 52nd Winter Conference on Brain Research, Snowmass, CO February, 2019 **Recipient: Panel Travel Fellowship** (Invited speaker)
22. Symposium: *Neuroendocrine and neuro immune mechanisms of addiction* 53rd Winter Conference on Brain Research, Big Sky, MT January 2020 (Invited speaker)
23. Symposium: *Cross-Species Evidence for Novel Therapeutic Targets in Alcohol Use Disorder: A phase 2 randomized cross-over drug-alcohol interaction study with the mGluR5 negative allosteric modulator GET 73 in individuals with alcohol use disorder.* Research Society for Alcoholism (RSA), New Orleans, LA June 2020, *Cancelled, carryover June 2021* (Invited speaker)
24. Symposium: *The stress of alcohol addiction-glucocorticoid receptors as an emerging drug target,* Research Society for Alcoholism (RSA), New Orleans, LA, 2020 June 2020, *Cancelled, carryover June 2021, (Discussant)*
25. COBRE Retreat: *Oxytocin to reduce stress-induced craving in patients with opioid use disorder.* September 2020, *Virtual* (Invited speaker)
26. 2020 Symposium on Substance Use Research, Rural Drug Research (RDAR), COBRE Opioid and Overdose, West Virginia Clinical and Translational Science Institute (WVCTSI): *Oxytocin to reduce stress-induced relapsing in patients with opioid use disorder.* November 2020, *Virtual* (Invited speaker)
27. Symposium: *Cross-Species Evidence for Novel Therapeutic Targets in Alcohol Use Disorder: A phase 2 randomized cross-over drug-alcohol interaction study with the mGluR5 negative allosteric modulator GET 73 in individuals with alcohol use disorder.* Research Society for Alcoholism (RSA), Austin, TX June 2021 (Invited speaker)
28. Symposium: *The stress of alcohol addiction-glucocorticoid receptors as an emerging drug target,* Research Society for Alcoholism (RSA), Austin, TX, June 2021 (Discussant)
29. Symposium: *Emerging Research on Addiction and Overdose. Oxytocin to reduce stress-induced opioid relapse: Human Laboratory Study.* Rhode Island IDeA Network of Biomedical Research Excellence (RI-INBRE), Virtual North East Regional IDeA Conference, August 2021
30. Invited Talk: *Randomized controlled trials for alcohol use disorder during the COVID-19 pandemic.* NIH, Translational Addiction Medicine Branch – NIDA IRP, October 20th, 2021
31. COBRE Retreat: *Oxytocin to reduce stress-induced craving in patients with opioid use disorder.* November 2021, (Invited speaker)
32. Symposium: *Peripheral Signals Suggest Central Targets for the Treatment of Drug and Alcohol Addiction:* 54th Winter Conference on Brain Research, Snowmass, CO February 2022 (Invited speaker, talk done by Joshua Brown, MD, PhD)
33. Symposium: *Novel approaches targeting alcohol metabolism to treat alcohol use disorder.* Research Society for Alcoholism (RSA), Orlando, FL, June 2022 (talk done by Roberta Perciballi, MD, post-doc)
34. Symposium: *Preclinical Models for Polysubstance Use and Multidrug Interactions.* Research Society for Alcoholism (RSA), Orlando, FL, June 2022 (discussion done by Falk Lehoff, PhD)
35. Presentation: *Mifepristone as a pharmacological intervention for stress-Induced alcohol craving: a translational randomized trial.* Corcept Therapeutics Research Conference, Halfmoon Bay, CA September 2022 (Invited speaker)

INVITED INTERNATIONAL PRESENTATIONS AND SYMPOSIA

36. Symposium: UNICAM, Alcol a Nudo. *A translational investigation on the role of Corticotropin Releasing Factor Binding Protein in alcohol consumption: a strange case of Dr. Jekyll and Mr. Hyde?* Università Camerino (UNICAM), Italy October 2016 (Invited speaker)
37. Young Investigator Symposium: Volterra Conference *Alcoholism and Stress: A Framework for Future Treatment Strategies. Translational models to investigate allosteric modulation as strategy for small molecules as first-generation alcohol use disorder therapeutics*. Volterra, Italy, May 2017 **Recipient: Volterra New Investigator Award**
38. Symposium: European Society for Biomedical Research on Alcoholism (ESBRA), Heraklion Greece. *Subgroups to predict pharmacotherapy response in Human Alcohol Laboratory Studies*, October 2017 (Invited speaker)
39. Zardi – Gori Foundation Scientific Conference, *Alcohol Use Disorder: from Bench to Bedside, A translational approach for investigating stress-related alcohol use disorder*, Milan, Italy, November 2017 (Invited speaker)
40. Symposium: International Society for Biomedical Research on Alcoholism (ISBRA), Kyoto Japan: *Translational investigations on allosteric modulators (AM): Allosteric modulators targeting the corticotropin releasing factor* September 2018 (Chair and speaker)
41. Symposium: International Society for Biomedical Research on Alcoholism (ISBRA), Kyoto Japan. *Promising Targets of Alcohol Addiction: Promising Targets of Alcohol Addiction* September, 2018 **Recipient: NIH/NIAAA International Travel Award and Brown University Faculty Travel Award** (Invited speaker)
42. Symposium: European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France: *The role of hormones in Alcohol Use Disorder* September, 2019, abstract in Alcoologie et Addictologie, 41 (3): 378, 2019 (Chair and speaker)
43. Symposium: European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France: *Corticotropin releasing factor binding protein in the amygdala: the good, the bad and the ugly* September, 2019, abstract in Alcoologie et Addictologie, 41 (3): 378, 2019 (Chair and speaker)
44. Symposium: European Society for Biomedical Research on Alcoholism (ESBRA), Lille, France: *Medications with novel mechanisms for the treatment of alcohol use disorders* September 2019, abstract in Alcoologie et Addictologie, 41 (3): 378, 2019 (Chair and discussant)
45. UNICAM University of Camerino, Italy. PhD talks: *Oxytocin to reduce stress-induced craving in patients with opioid use disorder*. November 2020, *Virtual* (Invited speaker)
46. UNICAM University of Camerino, Italy. Talk Series: Un dottorando in 40 minuti - An initiative to keep going, Second Edition. *Pharmacotherapies for Alcohol Use Disorder the US and Europe*, February 2021 *Virtual* (Invited speaker)
47. Symposium: Volterra Conference *Alcoholism and Stress, Towards Personalized Treatment for Alcohol Use Disorder: Focus on α 1-blockade*. Volterra, Italy, May 2021 (Invited speaker, postponed due to COVID)
48. UNICAM University of Camerino, Italy. PhD Talk Series: *PhD Updates and Research Accomplishments*, February 24th 2022 *Virtual*

GRANTSCURRENT GRANT SUPPORT

1. UE5 DA056914 (PI: Breazeal) 07/20/2022 – 07/19/2027
 NIH/NIDA \$1,717,627
Program on Entrepreneurship and Innovation for Biomedical Product Development
 This is a collaboration between MIT/Brown/Harvard for developing a proposal for an academic program for biomedical and neuroscience researchers working in the field of substance use disorders (SUDs) a

first-of-its-kind, integrated curriculum on innovation, entrepreneurial problem solving and biomedical product development. Our program's goal is to promote technological and commercial innovations for SUDs prevention, diagnosis and treatment.

Role: Principal Investigator Brown University Subaward (MIT primary)

2. P20 GM130414 (PI: Monti; Pilot MPI: Eaton and Capone) 07/22/2022 - 07/21/2023 11
Brown University \$60,000
CNS response of MDMA-assisted therapy for the treatment of co-occurring posttraumatic stress disorder and alcohol use disorders in combat veterans
Role: Mentor
3. Office of the Vice President Research (MPI: Eaton, Haass-Koffler) 02/22/2022 - 02/21/2023
Brown University \$60,000
Safety, feasibility, and acceptability of MDMA-assisted therapy for the treatment of co-occurring posttraumatic stress disorder and alcohol use disorders in combat veterans.
Role: Principal Investigator
4. R01 AA027760 Diversity Supplement (PI: Haass-Koffler) 09/10/2019 - 09/09/2024
NIH/NIAAA \$80,992
A focus on alpha-1 blockade as a novel pharmacological treatment for alcohol use disorder. This diversity supplement is supporting a PhD student in neuroscience from an underrepresented minority and focuses on the mediation of the pro/anti-inflammatory processes on alcohol-related behaviors in individuals with AUD taking doxazosin (alpha-1 antagonist) or placebo.
Role: Principal Investigator **[NCT04135846]**
5. R21 AA027273 (PI: Jin) 09/10/2021 - 09/08/2023
NIH/NIAAA \$224,250
Targeting stress reactivity, alcohol craving, and drinking with pioglitazone
Role: Collaborator
6. R21 AA027614 (PI: Haass-Koffler) 04/10/19– 03/31/2023 (NCE)
NIH/NIAAA \$250,000
Probenecid as a pharmacotherapy for alcohol use disorder
This research examines the alcohol-probenecid interaction in patients with alcohol use disorder
Role: Principal Investigator **[IND135570; NCT04051619]**
7. R01 AA027760 (PI: Haass-Koffler) 09/10/2019 - 09/09/2024
NIH/NIAAA \$2,460,664
A focus on alpha-1 blockade as a novel pharmacological treatment for alcohol use disorder. The goal of this RCT is to understand the role of stress in the development of AUD therapies that target noradrenergic blockade. To achieve these goals, this study proposes a 16 week, between-subject, double-blind, RCT with doxazosin compared to placebo
Role: Principal Investigator **[NCT04135846]**
8. P20 GM130414 (PI: Monti; Pilot PI: Haass-Koffler) 11/06/2019 – 12/30/2022
NIH/NIGMS - Centers of Biomedical Research Excellence (COBRE) \$50,000
Oxytocin to Reduce Stress-Induced Craving in Patients with Opioid Use Disorder
This research examines the role of intranasal oxytocin on stress and cue-induced opioid craving in patients with opioid use disorder.
Role: Pilot Project Leader **[IND135570; NCT04051619]**

9. Halon foundation (MPI: Haass-Koffler, Kaun, McGeary, White) 08/01/2019 – 07/31/2022
 Hubert & Richard Hanlon Trust Grant Award \$300,000
The Stress Factor: Understanding the Role of Norepinephrine in Alcohol Use Disorder
 This study stemmed from the R01 AA027760 (PI: Haass-Koffler) and translates work from flies (*Drosophila*) to humans with the goal of understanding the how α 1-blockade (via doxazosin) affects the brain (fMRI) during stress conditions.
 Role: Principal Investigator (MPI) [NCT04135846]

10. R01 AA026589 (PI: Sheffler; Subaward PI: Haass-Koffler) 05/01/2019 – 03/31/2023 (NCE)
 NIH/NIAAA \$865,843
Lead optimization of novel CRFBP-CRFR2 complex modulators for alcohol use disorder
 This project will develop CRF-BP/CRFR2 negative allosteric modulators (NAMs) using structure activity relationship (SAR) and electrophysiology for treating Alcohol Use Disorder
 Role: Principal Investigator Brown University Subaward (SBP Primary)

11. K01 AA026874 (PI: Goodyear) 04/15/2019 – 04/14/2024
 NIH/NIAAA \$957,895
The neural mechanisms associated with alcohol and cigarette craving in alcohol use disorder smokers during oxytocin treatment
 Non-treatment-seeking AUD smokers will be recruited to participate in a between-subjects, placebo-controlled, randomized pilot fMRI study. Participants will undergo an fMRI scan in conjunction with an alcohol-olfactory cue-reactivity task.
 Role: Primary Mentor and IND Holder [IND135570; NCT04071119]

12. P20 GM130414 (PI: Monti; CLC project MPI: Haass-Koffler, Metrik) 01/01/2021 – 08/02/2022
 NIH/NIGMS - Centers of Biomedical Research Excellence (COBRE) \$7,500
 Rapid Response Award: *The role of tetrahydrocannabinol in acute alcohol-induced inflammation.*
 The strategy of this proposal is to examine the mediating role of cytokines as a mechanism whereby THC acutely decreases alcohol consumption.
 Role: MPI [IND129490; NCT02983773]

PENDING GRANT SUPPORT

13. R01 AA030467 (PI: Haass-Koffler) 04/02/2023 – 04/01/2028
 NIH/NIAAA \$3,478,641
Sex differences in translational biobehavioral markers of alcohol use disorder.
 The main goal of this proposed work is to mechanistically evaluate the relationship between sex differences across species to improve AUD precision medicine, and further narrow the bench to bedside knowledge gap. The proposal is comprised of 3 Independent Aims: 1) Alcohol craving models; 2), Alcohol consumption models; 3) Central network engagement, with each Aim divided into 2 Parallel Sub-Aims: Human and Rats that will translationally test in parallel established alcohol domains.
 Role: Principle Investigator

14. R01 AA030888 (PI: Sheffler) 01/02/2023 – 01/01/2028
 NIH/NIAAA \$3,500,000
Optimization of Drug-like Properties of CRFBP-CRF2 Negative Allosteric Modulators for Alcohol Use Disorder
 This is a collaboration between Sanford Burnham Presby, University of Camerino, Italy and Brown University for developing NAMs that target the stress system.
 Role: Principal Investigator Brown University Subaward (SBP primary)

COMPLETED GRANT SUPPORT

1. R01 AA024091 (PI: Metrik) 03/31/2016 – 03/31/2020
 NIH/NIAAA \$506,516
Marijuana's impact on alcohol motivation and consumption.
 The strategy of this proposal is to use the most comprehensive controlled test characterizing marijuana's putative effects on alcohol craving.
 Role: Collaborator [IND129490; NCT02983773]
2. 5th \$100,000 Start a SUD StartupChallenge (PI: Murphy) 06/23/2020 – 06/22/2021
 NIH/NIDA \$100,000
 The Challenge goal is to support research ideas or technologies that would further an understanding of Substance Use Disorders (SUD) and will serve as a foundation for the development of successful new startups or products. We will develop a few candidate microspheres for limited *in vitro* data, to support a future SBIR application
 Role: Co-investigator
3. K01 AA023867 (PI: Haass-Koffler) 03/01/2016 – 02/28/2021
 NIH/NIAAA \$957,895
Mifepristone As A Pharmacological Intervention For Stress-Induced Alcohol Drinking
 This project tests a preclinical paradigm, paired to a human alcohol laboratory model to investigate whether mifepristone, a glucocorticoid receptor antagonist, reduces alcohol craving and consumption
 Role: Principal Investigator [IND121984; NCT02243709]
4. Rohsenow Pilot Project Award (PI: Haass-Koffler) 04/01/2020 – 03/31/2021
 CASS, Brown University \$2,000
Examining the Impact of the Rapidly Evolving COVID-19 Pandemic on Individuals with AUD Who Have Participated in Human Laboratory Studies
 This study evaluates longitudinally the effect of COVID-19 in the AUD population that have previously participated in human lab studies at CAAS. This study offers the unique opportunity to monitor in real time (by remote sessions) the effect of COVID-19 (e.g. isolation, stress, financial burden, risk) in a very clean sample where we have collected an enormous amount of data pre-COVID-19 (e.g. physical exam, psychiatric assessments, blood work).
 Role: Principal Investigator
5. P20 GM130414 (PI: Monti; PL: Haass-Koffler) 08/01/2019 – 10/01/2019
 NIH/NIGMS - Centers of Biomedical Research Excellence (COBRE) \$242,026
Oxytocin to Reduce Stress-Induced Craving in Patients with Opioid Use Disorder
 This research examines the role of intranasal oxytocin on stress and cue-induced opioid craving in patients with opioid use disorder.
 Role: Project Leader [IND135570; NCT04051619]
6. Research Excellence Award (PI: Goodyear) 09/05/2017 – 09/04/2018
 CAAS, Brown University \$7,930
The Neural Mechanisms Associated with Alcohol and Cigarette Craving During Olfactory Cues: a pilot fMRI study
 The overall goal of this study is to collect pilot data on the effects of olfactory alcohol cues on brain activation and on alcohol and cigarette craving in heavy-drinking smokers.
 Role: Mentor and Co-I
7. Rohsenow Pilot Project Award (PI: Haass-Koffler) 09/01/2017 – 08/30/2018
 CAAS, Brown University \$2,490

Integrated cue-reactivity paradigm and eye tracking procedure to assess selective attention to simultaneous alcohol and smoking cues: a pilot study

This study will test a behavioral alcohol-smoking cue-reactivity paradigm paired with the use of the eye tracking procedure, to assess the preferred attention to alcohol or smoking cues in heavy-drinking smokers.

8. Laboratorio Farmaceutico CT S.r.l (PI: Swift) 06/01/2014 – 02/31/2018
\$535,714
A Phase Ib/Ila, Cross-Over, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Safety and Pharmacodynamics Effects of GET 73 in Alcohol Dependent Subjects
The aims of this research are: 1) to examine the safety of a glutamate modulator medication, GET 73 in combination with alcohol and 2) to determine if GET 73 reduces craving and alcohol consumption in non-treatment seeking alcohol-dependent subjects in an alcohol self-administration paradigm
Role: Co-Investigator

9. Research Excellence Award (PI: Haass-Koffler) 01/15/2014 – 06/14/2016
CAAS, Brown University \$15,000
Pilot Study on the safety and efficacy of Mifepristone for the prevention of relapses of alcohol drinking
This study investigates the role of glucocorticoid-receptor antagonist in alcohol use disorder
Role: Principal Investigator [IND121984; NCT02243709]

10. Strategic Opportunities Exploratory Award (PI: Haass-Koffler) 01/15/2012 – 06/14/2012
University of California, San Francisco (UCSF) \$5,000
Preclinical imaging study of Corticotropin Releasing Factor Binding Protein using 7T Magnetic Resonance Imaging (MRI)
Role: Principal Investigator

11. R21/33 DA029966 (PI: Cosford/Bartlett) 2010 – 2012
NIH/NIDA \$423,032/\$487,500
Identifying Chemical Modulators of CRF-Binding Protein and CRF-Receptor Complexes
This project combines novel cell-based assays (CRF-BP-CRF-R2 receptor complex), high throughput screening, structure activity relationship analysis, chemistry-based 'hit to lead' optimization to generate a targeted library of novel ligands and compounds
Role: Collaborator (postdoc)

12. NIH Molecular Libraries Small Molecule Repository (MLSMR) (PI: Bartlett) 2010 – 2012
The compounds in the NIH/MLSMR library will be screened using the Corticotropin Releasing Factor (CRF)-Binding Protein and CRF-Receptor Complexes
Role: Collaborator (postdoc)

13. UCSF School of Pharmacy, Dean's Office and Clinical Pharmacy (PI: Haass-Koffler) 2009 – 2012
Training grant
Role: Fellow

UNIVERSITY TEACHING ROLES

- | | |
|------|--|
| 1999 | University of Minnesota, Twin Cities, College Science & Engineering, <i>Chemistry and Material Science in the conservation of mural paintings</i> , lecture for development of scientific approaches using chemistry and material science in mural paintings (25 graduate students in the Chemistry and Chemical Engineering programs) |
| 2000 | University of California, Berkeley, School of Chemistry, <i>The role of Chemistry in Art Conservation</i> , lecture for development of scientific approaches using chemistry for the authentication of easel |

- paintings, (150 undergraduate and graduate students in the Chemistry and Chemical Engineering programs)
- 2001 University of California, Berkeley, School of Chemistry, *From Chemistry Student to Research Chemist in Pharmaceuticals*, message to entering student at the University of California, Berkeley, (100 undergraduates and transfer students)
- 2007 University of California, Berkeley, School of Public Health, *Pharmacy and Pharmaceutical Science Pathway, a new avenue for pharmacists to perform research* (125 undergraduates)
- 2006 - 2007 University of California, San Francisco, School of Pharmacy, *Physiopathology of Addiction*, organized and administered series of lectures as UCSF Drug Abuse Awareness Coordinator for the California Society of Health-Systems Pharmacists on the physiopathology of addiction of drugs of abuse. Lectures included: the abuse of dextromethorphan, GHB rape drug, and presentation of a recovering addict pharmacist (120 UCSF Pharm.D. students and faculty)
- 2009 - 2012 University of California, San Francisco, School of Medicine, Seminar Series, Clinical Pharmacology and Experimental Therapeutics for approximately (3-10 Clinical fellows, MD, PhD and PharmD)
- 1) *HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin*
 - 2) NIH Principles of Clinical Pharmacology, *Cardiovascular Safety of Medications treatment for ADHD*
 - 3) NIH Principles of Clinical Pharmacology, *System pharmacology: Inflammation and Immunomodulation*
 - 4) *Neurotransmitters: Use in clinical practice as biomarkers of nervous system function*
 - 5) *Pharmacokinetics: Drug-Drug interactions*
- 2009 - 2012 Gallo Center at UCSF, Neuroscience, Microscopy and Visualization: Lecturer and technical support for the Neuroscience Department, (50 students, graduate, postdocs, faculty)
- 1) *Imaris Neuroscience microscopy/software interface*
 - 2) *In vivo Microscopy: applications in Neuroscience*
- 2009 - 2012 Gallo Center at UCSF, Neuroscience, Medications Development Group, Mentor for rotating students: undergraduate (UC Berkeley and Merritt College), graduate and pharmacy (Touro University and UCSF) students
- 2010 - 2011 University of California, San Francisco, School of Pharmacy, Pharmaceutical Sciences Pathway seminar series: *From Pharmaceutical Science student to UCSF fellow*, lecture for Pharm.D. students interested in performing research under a faculty advisor across multiple schools, (3-10 third year PharmD students) in the Winter quarter each year
- 2011 - 2012 University of California, San Francisco, School of Pharmacy, Pharmacokinetic and Biopharmaceutical: coordinating and administering lectures and workshop for second year PharmD students in Drug-Drug interaction, lectures, workshop (120 PharmD students) in the Fall/Winter quarter each year
- 2013 Northeastern University, Bouvé College of Health Science, Pharmaceutical Science *Pharmacogenomics*, Three-hour lecture lectures within the Pharmacokinetics/Pharmacodynamics course for Pharmaceutical Science and Biotechnology (66 M.S. and PhD students)
- 2013 - pres. Northeastern University, Bouvé College of Health Science, Pharmacy School, *Pharmacogenomics*, six lectures within the Pharmacology and Medicinal Chemistry II (157 PharmD students), in the Summer each year
- 2014 – 2015 Northeastern University, Bouvé College of Health Science, Pharmaceutical Science, *Drug Discovery and Development of Medications for treating Drug Dependence & Addictions*. Lecture within Drug Discovery course, (50 MS and PhD students), in the Fall each year
- 2015 – pres. Brown University, T32 Core Seminar Series, CAAS, *Ethics: Intellectual Properties*. Butler Hospital, (30 Clinical Psychology and T-32 Postdoctoral fellows)

- 2016 – pres. Brown University, T32 Core Seminar Series, CAAS, *Psychosocial and Pharmacologic Treatment of Substance Use Disorders: Pharmacological Treatment for Addictions: the example of Alcohol Use Disorder from Experimental Therapeutics perspective*, (T-32 Postdoctoral fellows)
- 2017 – pres. Brown University, T32 Core Seminar Series, CAAS, *Etiology of Substance Abuse: The role of stress on substance use, craving and relapse* (T-32 Postdoctoral fellows)
- 2018 Research Society for Alcoholism (RSA):
- *Skill Blitz session*, host a round table (graduate/post-baccalaureate trainees)
 - *NIAAA and the RSA Education Committee workshop*, facilitator “Getting Your First Research Grant” breakout, and a “Career Development Award” Breakout (postdocs and junior investigators)
- 2019 – pres. Brown University, School of Public Health: Pharmacological approaches for Alcohol Use Disorder in the *Alcohol Use and Misuse Course SPH1540*
- 2020 – pres. Brown University, T32 Core Seminar Series, CAAS, *Grant Writing Series: The Approach Section* (T-32 Postdoctoral fellows)

MENTORING, SUPERVISING AND THESIS COMMITTEE ROLES

(see addendum for mentees accomplishments)

- 2013 – 2016 **Elie G Aoun, MD** Resident, Department of Psychiatry and Human Behavior, Alpert Medical School, Brown University (Mentor)
- 2015 – 2016 **Danielle E Giovenco, ScM, PhD**, Department of Behavioral and Social Science, School of Public Health, Brown University (Mentor and Supervisor)
- 2016 – 2017 **Sarah E Eltinge, ScB, AB**, School of Public Health, Brown University (Senior Honor Thesis Advisor)
- 2016 – 2018 **Rachel Souza, ScM**, Department of Behavioral and Social Science, School of Public Health, Brown University (Mentor and Thesis Advisor)
- 2016 – 2019 **Paul M Wallace, MD**, Medical Student Alpert Medical School, Brown University (Mentor)
- 2016 – 2019 **Kimberly Goodyear, PhD**, Department of Behavioral and Social Science, School of Public Health, Brown University (T-32 Postdoctoral Mentor)
- 2016 – 2019 **Victoria M Long, ScM**, Department of Behavioral and Social Science, School of Public Health, Brown University (Mentor, Thesis Advisor and Supervisor)
- 2018 – 2020 **Bianca Persaud, AB/PLME** Brown Program Liberal Medical Edu (Mentor, Thesis Advisor and Supervisor)
- 2018 – 2019 **Robert Perciaballi, MD**, Internal Medicine and Toxicology and Experimental Therapeutics, La Sapienza University Rome Italy, Research Scholar (Mentor)
- 2019 – pres. **Zoe E Brown BA**, Center of Alcohol Addiction Studies, Brown University, Research Assistant (Mentor)
- 2020 – 2021 **Deena Haque, ScB candidate**, Neuroscience (Mentor)
- 2020 – 2021 **Arianna Ferretti, ScB**, Neuroscience (Mentor and Adviser for independent studies)
- 2020 – pres. **Talia Vasaturo-Kolodner, ScB candidate**, Neuroscience (Mentor)
- 2020 – pres. **Dallece E Curley, PhD candidate**, Neuroscience (Mentor and Thesis Advisor)
- 2021 – 2021 **Jeffery Rasmussen, PhD student**, Neuroscience (Rotation Student)
- 2021 – pres. **Morgan Nelson, BS, ScM candidate**, BioMed: Biotechnology (Mentor, Independent Study)
- 2021 **Jorge Avila PhD**, American College Neuropsychopharmacology (ACNP), Travel Awardee (Mentor)
- 2021 – 2022 **Liam Haass ScB candidate**, Neuroscience, Class 2023 (Mentor)
- 2021 – pres. **Prahbjot Singh ScB candidate**, Neuroscience, Class 2023 (Mentor)
- 2021 – pres. **Morgan Nelson BS, ScM candidate**, Molecular Pharmacology, Physiology and Biotechnology Class 2022 (Mentor and Thesis Advisor)
- 2021 – pres. **Brian Gully, MA**, Center of Alcohol Addiction Studies, Brown University, Research Assistant (Mentor)

- 2021 – pres. **Ryan Rhew ScB candidate**, Neuroscience, Class 2024 (Mentor)
 2021 – pres. **Paul Soliman ScB candidate**, Neuroscience, Class 2024 (Mentor)
 2022 – pres. **Robert Perciballi, MD**, Postdoctoral Research Fellow (Mentor)
 2022 **Jamie Catalano, ScM**, PhD Candidate Molecular Pharmacology and Physiology Graduate Program (Thesis Committee)
 2022 – pres. **Peter Sage ScB candidate**, Neuroscience, Class 2024 (Mentor)

MENTOR TRAINING PROGRAM

- 2019 Center for AIDS Research (CFAR) Mentor-the-Mentor Certification, NIH National Research Mentoring Network (NRMN)
 2020 Advance-CTR Clinical Translational Research and Brown University, *Obtain K awards and transition to the R series Advance-K Scholars program*

HOSPITAL TEACHING ROLES

- 1994 - 1995 Red Cross, Assistant in the training of International Humanity Law for Army Military and Red Cross Officers (50 military personnel)
 1994 - 1995 Red Cross, Qualified Counselor of International Humanity Law, Marina di Massa, 1994. Assistant in the training of International Humanity Law for Army Military and Red Cross Officers (50 military personnel)
 1994 Italian Air Force, School Medicine, Rome. Lieutenant in charge training nurses' qualification Air Mobile Search & Rescue, (30 military personnel)

INDUSTRY APPOINTMENTS AND PARTNERSHIPS

- 2002 - 2005 Roche Bioscience, Palo Alto, CA, Discovery Pharmaceuticals, Research Chemist, Research Associate II
 2013 - pres. Corcept Therapeutics, pharmaceutical company developing products that regulate the effects of cortisol and deal with severe metabolic disorders, Menlo Park, CA
 2016 - pres. Gravitas Bioscience, Inc, Providence, RI. Scientific Review Board
 2016 - pres. Laboratorio Farmaceutico CT S.r.l, San Remo, Italy. Scientific Review Board

ADDENDUM: MENTORING AND SUPERVISING ROLES

MENTEES ACCOMPLISHMENTS IN THE CLINICAL NEUROSCIENCE LABORATORY AT BROWN UNIVERSITY AND THEIR CURRENT POSITION					
Position in the Clinical Neuroscience Laboratory	Trainee	Role	Year	Achievements in the Laboratory	Position after the Clinical Neuroscience Laboratory
Psychiatry Resident Alpert Medical School	Elie G Aoun, MD	Mentor	2013 2016	<ul style="list-style-type: none"> American Academy of Addiction Psychiatry (AAP), Aventura, FL; Poster Recipient: 9th highest score out of 200 submissions and Travel Award, 2014 AAP, Huntington Beach, CA; Poster Selected: for Medscape Report, 2015 R25 Grant Awardee for the Brown University Psychiatry Training Research Track, National Institute of Mental Health (R25MH101076), 2014-2015 American Association of Directors of Psychiatric Residency Training (AADPRT), International Medical Graduate award, 2016 AAP American Psychiatric Leadership Award, 2016 AAP Associate Chair Program Committee, 2016-2018 APA – SAMSHA Substance Abuse and Minority Fellowship awardee, APA, 2016 -2017 Stepping Up National Summit/APEX (American Psychiatric Excellence Award) Travel Award, APA, 2016 AADPRT International Medical Graduate Award, AADPRT, 2016 Addiction Psychiatry Fellow, University California, San Francisco, CA (2016-2017) Forensic Psychiatry Fellow, Columbia University, NY (2017-2019) 3 publications 	New York University Assistant Professor
ScM candidate Class 2016 Research Assistant Behavioral Social Sciences	Danielle E Giovenco, ScM, PhD	Mentor Supervisor	2015 2016	<ul style="list-style-type: none"> Graduated MSc, Behavioral Social Science, School Public Health, 2016 PhD Candidate, Epidemiology, Gillings School of Global Public Health, University North Carolina 1 publication PhD Candidate, Epi Gillings School of Global PH, University North Carolina 	Postdoctoral Fellow Brown University
ScB/AB candidate Class 2017 School Public Health	Sarah E Eltinge, ScB, AB	Senior Honor Thesis Advisor	2016 2017	<ul style="list-style-type: none"> Award for Excellence in Public Health Honors Thesis, 2017 Sc.B. Statistics & A.B. Public Health, 2017 Selected for the Brown School of Public Health highlights SPH student story, 2017 Johnson & Johnson Health Technology Center, Research Analyst, Providence, RI (2017-2019) 1 publication 	Data Engineer Rhode Island Quality Institute
ScM candidate Class 2019 Behavioral Social Sciences	Rachel Souza, ScM	Mentor Thesis Advisor	2016 2018	<ul style="list-style-type: none"> Accepted to Master program, Behavioral Social Science, School Public Health, Brown, 2017 NIH/NIAAA Research Society for Alcoholism, Student Merit Award, 2018 1 publication 	Philadelphia College of Osteopathic Medicine
MD candidate Class 2019 Alpert Medical School	Paul M Wallace, MD	Mentor	2016 2019	<ul style="list-style-type: none"> Alpert Medical School, Brown University Summer Assistantship, 2016 Summer Institute for Medical Students (SIMS), Hazelden Betty Ford Foundation, 2016S Society of Teachers of Family Medicine Conference on Medical Student Education, Naloxone in the homeless community project, Anaheim, CA, travel funded by SAMSHA, 2017 1 publication 	Psychiatry Residency University California San Francisco (UCSF)
T-32 Postdoctoral Fellow Behavioral Social Sciences	Kimberly Goodyear, PhD	T-32 Mentor IND Holder	2016 2019	<ul style="list-style-type: none"> Research Society of Alcoholism (RSA) Student Merit Award, 2016 NIH/NIAAA Travel Award Volterra Conference, Italy2017, ASCP Clinical Trials Workshop Fellowship, NY, 2017 RSA Junior Investigator Award, 2017 Research Excellence Award, NCATS-funded partnership to collaborate among early-career scholars to focus on Radical Solutions to the Opioid Misuse Epidemic, 2017 K01 AA026874 The Neural Mechanisms Associated With Alcohol and Cigarette Craving in AUD Smokers During Oxytocin Treatment, 2019 1st Prize Postdoctoral Poster Award, Brain Mind, Brown, 2019 9 publications 	Assistant Professor CAAS Behavioral Social Sciences School of Public Health Brown University

Position in the Clinical Neuroscience Laboratory	Trainee	Role	Year	Achievements in the Laboratory	Position after the Clinical Neuroscience Laboratory
ScM candidate Class 2019 Research Assistant Behavioral Social Sciences	Victoria M Long, ScM	Mentor Supervisor	2016 2019	<ul style="list-style-type: none"> Graduate ScM Behavioral Social Science School Public Health, Brown, 2019 Recipient of the Public Health Impact Award, 2019 Selected Article: ACER Article of Public Interest (API) 7 publications 	Research Associate Cengage
Brown Program Liberal Medical Edu (PLME) AB and MD	Bianca Persaud, AB	Mentor Senior Thesis	2018 2020	<ul style="list-style-type: none"> Public Health Honors Thesis, 2020 Graduated AB Public Health, 2020 	Warren Alpert Medical School Brown University
Research Scholar	Roberta Perciballi, MD	Mentor	2018 pres	<ul style="list-style-type: none"> Residency Program Internal Medicine and Toxicology and Experimental Therapeutics, La Sapienza University, Rome Italy, 2019 3 publications 	ASL Center for Treating Dependencies
ScB candidate Class 2020 Neuroscience	Harrison H Tran	Mentor	2016 2018	<ul style="list-style-type: none"> Karen T. Romer Undergraduate Teaching and Research Award (UTRA), 2017 Admitted to Harvard and University California San Francisco (UCSF) Medical School, 2021 3 publications 	University California San Francisco (UCSF) Medical School
ScB candidate Class 2021 Neuroscience	Arianna Ferretti	Mentor	2020 2021	<ul style="list-style-type: none"> BrownConnect Collaborative SPRINT Award (Projects for Research, Internships, and Teaching), 2020 	Research Assistant RI Hospital
Research Scholar	Wooyoung Jung, MD, PhD	Mentor	2020 2021		Psychiatrist South Korea, Hospital
PhD candidate Class 2024 Neuroscience	Jeffery Rasmussen ScM	Rotation student	2021		Harvard Medical School
CURRENT MEMBERS IN THE CLINICAL NEUROSCIENCE LABORATORY					
Research Assistant	Zoe E Brown, BS	Mentor Supervisor	2019 pres	<ul style="list-style-type: none"> Nominated for the SPH Staff Excellence Award in Innovation 2 publications 	
ScB candidate Class 2023 Neuroscience	Talia Vasaturo-Kolodner	Mentor	2020 pres	<ul style="list-style-type: none"> BrownConnect SPRINT UTRA in Fall 2022 "Hormones and Alcohol Use Disorder: A Secondary Analysis to Elucidate Therapeutic Targets" (\$1,200) 3 publications 	
ScB candidate Class 2023 Neuroscience	Deena Haque	Mentor	2020 2021	<ul style="list-style-type: none"> Bonner Community Fellowship, 2023 	
PhD candidate Class 2023 Neuroscience	Dallece Elena Curley, BS	Thesis Mentor	2020 pres	<ul style="list-style-type: none"> Science Mentoring & Diversity Program Biotechnology Program (SMDP) Award, 2021 Submitted NIH/NIAAA Diversity Supplement 2021 NSGP Graduate Student Council (GSC) Representative (2020-2021) Teaching Assistant for Experimental Neurobiology with Dr. John Stein (Spring 2021) GSC Finance Committee (2021-2022) NSGP Seminar Speaker Series Graduate Student Representative (2021-2022) Serving on the Graduate Labor Organization Grievance Committee (2021-2022) Society for Neuroscience's (SfN) Neuroscience Scholars Program (NSP) Associate Fellow (2021) NIAAA Diversity Supplement American Society of Microbiology, Judge for the ABRCM Conference (2021) Accepted to The Foundations of Clinical Research Program, Harvard Medical School K α τ Foundation Award to support Clin. Res. Certificate Program, Harvard Medical School Brown University International Travel Award for Studying at the University of Camerino, Italy 3 publications 	
ScB candidate Class 2023 Neuroscience	Liam Haas	Mentor	2021		
ScM candidate Class 2022 Biotechnology	Morgan Nelson, BS	Mentor	2021 pres	<ul style="list-style-type: none"> Poster at the Brown University SPH Research Day 	

ScB candidate Class 2023 Neuroscience	Prabhjot Singh	Mentor	2021 pres	<ul style="list-style-type: none"> Accepted to the School of Medicine with the FlexMed program at Mt Sinai BrownConnect SPRINT UTRA in Fall 2022 "Strategies for Overcoming Barriers to AUD Clinical Trial Recruitment and Retention" (\$1,200)
Research Assistant	Brain Gully, MA	Mentor Supervisor	2021 pres	
ScB candidate Class 2024	Ryan Rhew	Mentor	2021 pres	<ul style="list-style-type: none"> BrownConnect SPRINT UTRA in Fall 2022 "Presence of sensitization in clinical alcohol cue-reactivity assessments: a secondary analysis" (\$1,600)
ScB candidate Class 2024	Paul Soliman	Mentor	2021 pres	<ul style="list-style-type: none"> BrownConnect SPRINT UTRA in Fall 2022 "Placebo Use in Clinical Trials with Psychedelics" (\$1,200)
Postdoctoral Research Associate	Roberta Perciballi, MD	Mentor	2022 pres	<ul style="list-style-type: none"> Returning as postdoc from Research Scholar (2019) position 3 publications
ScB candidate Class 2024	Peter Sage	Mentor	2022 pres	